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Abstract 
 Tumor recurrence after chemotherapy is a major cause of patient morbidity and 
mortality.  Recurrences are thought to be due to small subsets of stem-like cancer cells 
that are able to survive chemotherapy and drive tumor re-growth.  A more complete 
understanding of stem-like cancer cell regulation is required to develop therapies to better 
target and eliminate these cells. 
 Slow-cycling stem cells are integral components of adult epithelial tissues and 
may give rise to cancer stem cell populations that share similar characteristics.  These 
slow-cycling adult stem cells are inherently resistant to traditional forms of chemotherapy 
and transference of this characteristic may help to explain therapy resistance in cancer 
stem cell populations.  Using a novel application for the proliferation marker CFSE, we 
have identified populations of slow-cycling cancer cells with tumor initiating capabilities.  
As predicted, slow-cycling cancer cells exhibit a multi-fold increase in chemotherapy 
resistance and retain the ability to re-enter the cell cycle. Furthermore, we observed 
consistent over-expression of the CDK5 activator, p35, in slow-cycling cancer cells.  
Manipulation of p35 expression in cancer cells affects cell cycle distribution and survival 
when these cells are treated with traditional forms of chemotherapy.  Additionally, we 
demonstrate that alterations in p35 expression affect BCL2 levels, suggesting a 
mechanism for the survival phenotype. 
 Combined, our data suggest a model whereby slow-cycling stem-like cancer cells 
utilize the p35/CDK5 complex to slow cell cycling speed and promote resistance to 
chemotherapy.  Future p35 targeting, in combination with traditional forms of 
 vii 
chemotherapy, may help eliminate these cells and reduce tumor recurrence rates, 
increasing long-term patient survival.   
 viii 
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Chapter I: 
Quiescent, Slow-cycling Stem Cell Populations in Cancer 
 
The Mammalian Cell Cycle and Quiescence 
 The standard mammalian cell cycle is a tightly controlled process consisting of 
four major phases:  gap 1 (G1), synthesis (S), gap 2 (G2), and mitosis (M) (Figure 1.1).  
Although thousands of proteins play roles in the cell cycle, the process is primarily 
regulated by a family of proteins known as the cyclin-dependent kinases (CDKs). 
Activity of specific CDK family members increases and decreases throughout the cell 
cycle, phosphorylating proteins that drive major checkpoints of the cell cycle.   
Activation and context specific activity of the CDK family is dependent on binding to 
one or more cyclin proteins during the correct phase of the cell cycle.  The G1 phase 
cyclins (cyclin D1, D2, and D3) bind and activate CDKs 4 and 6 in the G1 phase.  During 
this phase, cells begin to increase in size, protein mass, and organelles in preparation for 
division.   Importantly, G1 is also a time for monitoring both external and internal 
signaling, ensuring proper conditions for cell division (1).  When both external and 
internal signals are appropriate, the cyclin D/CDK4 complex helps initiate activation of 
the G1/S cyclin E complex, which binds CDK2, allowing for the phosphorylation of the 
Retinoblastoma (Rb) family of proteins (2).  Phosphorylation of Rb deactivates the 
protein, freeing the cell cycle driver E2F to push cells through the first major regulatory 
checkpoint known as “Start.”  After passing “Start,” a cell becomes committed to 
completion of the cell cycle and enters S phase, where DNA is duplicated. The S phase  
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Figure 1.1:  Mammalian cell cycle 
The cell cycle consists of four major phases: Gap phase 1 (G1), Synthesis (S), Gap phase 
2 (G2), and Mitosis (M).  Driving progression through these phases are cyclin dependent 
kinases (CDKs) whose activity is regulated by binding of specific cyclin activators (Cyc).  
During G1, CDKs 4 and 6 bind Cyc D family members to regulate cell growth and 
organelle expansion.  Transition into S is controlled by the Cyc E and CDK2 complex.  S 
phase is further regulated and sustained by Cyc A binding CDK2.  Finally, cells are driven 
through G2 and M by CDK1 activated by either Cyc A or Cyc B.  Stem cell populations 
temporarily exit the cell cycle into G0.  Maintenance and re-entry from G0 is regulated by 
CDK5 binding its cyclin-like activator p35. 
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cyclin A binds CDKs 1 or 2 to drive the cell though both S and G2 phases.  The G2 phase 
is an additional time for cell growth and serves as a pause prior to commitment to 
mitosis, a second major regulatory step (3).  The G2/M checkpoint ensures faithful DNA 
replication and a continued favorable division environment.  Finally, the M phase cyclin 
B binds and activates CDK1, phosphorylating different targets from the cyclin A/CDK1 
complex, pushing the cell though the G2/M checkpoint and into mitosis.  During the 
tightly regulated M phase, duplicate chromosomes are segregated and the cytoplasm is 
divided, completing the formation of two daughter cells.   
 Not all cells continuously progress through the cell cycle, but instead, may exit 
the cycle in a state termed G0 or quiescence.  Quiescence is generally achieved through 
the activity of cyclin dependent kinase inhibitors (CKIs) that primarily block binding of 
cyclin proteins to CDKs.  The INK4/ARF CKI family of proteins (p16, p18, and p19) 
target CDK4/6, leading to G1 stage arrest while the Cip/Kip CKI family of proteins (p21, 
p27, and p57) targets G1/S phase complexes, leading to late stage G1, S, and potentially 
G2/M arrests (4).  In healthy adult tissues, the Cip/Kip family members p21, p27, p57 
likely play an important role in controlling self-renewal of neural and hematopoietic stem 
and progenitor cells (5-7), while INK4/ARF family members may control brain, lung, 
and pancreatic stem cell proliferation (8-10).  These data suggest an important role for 
quiescence in adult tissue homeostasis and stem cell populations.  
 Interestingly, the CDK family member, CDK5, may play an important role in the 
maintenance of cell cycle arrest.  Like other CDK family members, CDK5 requires the 
presence of one of its cyclin-like binding partners (p35 or p39) for activation (11).  Little 
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is known about the functional differences between p35 and p39, but knock out studies in 
mice suggest at least some functionally independent roles for the two activators (12).  
The best studied of the two activators, p35, has no sequence homology with the cyclin 
family, but does appear to share structural homology and is believed to function in a 
similar manner (13).  The activity level and target specificity of CDK5 is dependent on 
binding either a 35 kD form of p35 or a more stable, highly active 25 kD form.  In some 
cases, binding the 35 kD form may have important differences in functional implications 
for CDK5 apart from binding the 25 kD form (14).  Unlike other CDK family members, 
the p35/CDK5 complex has no known role in driving the cell cycle forward, but may 
instead function in tandem with CKIs to block progression of the cell cycle.  In the 
context of developing neurons, p35/CDK5 has been demonstrated to bind to and 
translocate with p27 into the nucleus where they work in tandem to inhibit cell cycle 
progression (15).  Additionally, loss of p35 has been demonstrated to decrease cell cycle 
exit in osteosarcoma cells induced to express p16, suggesting a cooperative role between 
the two proteins (16).   
 
Adult Stem Cells and Quiescence 
 In tissues like those of the intestine and skin, new cells are continuously required 
to replace those that are lost to the environment.  To facilitate this constant need for new 
cells, some epithelial tissues are arranged hierarchically with slowly proliferating stem 
cells that asymmetrically divide to give rise to a new stem cell and a rapidly dividing cell 
called a transit amplifying (TA) cell (17).  TA cells proliferate quickly for a limited 
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number of divisions, allowing for the high degree of cell proliferation necessary to 
sustain adult tissues.  Adult stem cells are also critical for continued normal tissue 
homeostasis and in response to wounding for many of the epithelial tissues of the body.  
Adult stem cells are characterized by their ability to self-renew indefinitely and produce 
progeny capable of differentiating and repopulating tissue specific lineages (18).  
Populations of adult stem cells have been identified in tissues throughout the body, 
including the skin (19-21), mammary glands (22, 23), intestine (24, 25), prostate (26), 
brain (27), and the hematopoietic system (28, 29).  Infrequent division or a quiescent 
nature is not definitive for adult stem cells, but is suggested to be important for 
maintenance of many adult stem cell pools.  Evidence suggests that quiescence may play 
an important role in protecting stem cells from exhausting their proliferative capacity, 
inhibiting differentiation, and limiting accumulation of mutations which may occur 
during frequent rounds of DNA synthesis (30-32).  
 Initial efforts to identify and study adult stem cells took advantage of the slow-
cycling nature of stem cell populations in studies employing pulse/chase methodology 
(19, 24).  In these studies, DNA in cells was labeled with either tritiated thymidine (3H-
TdR) or 5-bromo-2’-deoxy-uridine (BrdU), repeatedly administered to mice or cultured 
cells.  DNA labeling was followed by a chase period, in which rapidly proliferating TA 
cells divided the label between daughter cells, consequently diluting the label.  In 
contrast, slow-cycling stem cells underwent fewer divisions and retained detectable 
quantities of label for much longer periods of time.  Cotsarelis et al. demonstrated that 
label retaining cells (LRCs) were exclusively present in the stem cell niche of the mouse 
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hair follicle known as the “bulge”, located adjacent to the hair follicle and just below the 
epidermis (19).  These cells were found to be relatively stem-like: “primitive” in 
cytoplasmic contents, structurally similar to other putative stem cell populations, and able 
to be stimulated to proliferate.  Cells present in the bulge region have been 
experimentally shown to be quiescent for up to 1 year (33), and based on the hair growth 
cycle of scalp skin can likely remain quiescent for up to 5 years. Under correct 
stimulation, bulge cells from human skin can differentiate into epidermal, sebaceous and 
hair follicle lineages in vitro (34).  These experiments demonstrate the important link 
between stem cell populations and the slow-cycling phenotype. 
 Although likely important for the maintenance of the stem cell pool, quiescence 
may not be a requirement for adult stem cells.  Using a lacZ construct under a conditional 
promoter for the stem cell associated protein leucine-rich G protein- coupled receptor 5 
(Lgr5), Jaks et al. demonstrated a distinct non-label retaining subpopulation of bulge cells 
that overlap with the CD34+/K15+ stem cell population at the resting stage (telogen) but 
not the growth phase (anagen) of the hair growth cycle (35).  Lineage tracing techniques 
confirmed that Lgr5+ cells actively cycled during normal homeostasis and had a 
multipotent phenotype.  Jaks et al. suggest that the Lgr5+ population of cells represents a 
cycling population of stem cells under normal conditions, whereas the label retaining 
CD34+/K15+ stem cells may represent a reserve population that is activated after tissue 
damage.  As yet, a conclusive relationship between these two populations cannot be 
firmly established.   
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 Similar label-retaining methods have been used to study slow-cycling cells in 
other tissues, such as the small intestine and colon.  Work conducted by Potten and 
colleagues identified slow-cycling LRCs at the +4 position of the colon crypt.  These 
crypt base cells were found to be maintained in a steady state of between four and six 
cells that go through division approximately once a week (36).  Upon irradiation, these 
cells demonstrated increased expression of the anti-apoptotic protein BCL2, decreased 
expression of the cell-survival regulator p53, and high activation and involvement in 
clonogenic regeneration of the crypt, suggesting a stem cell phenotype of crypt base cells.  
Two additional studies involving the putative stem cell associated RNA binding protein 
Musashi-1 (Msi1) again demonstrated a link between slow-cycling cells and the stem cell 
phenotype through co-localization of Msi1 with colon LRCs (37, 38).  
 From the evidence collected in these studies and others, a model has been 
proposed in which slow-cycling stem cells, found at the base of the crypt, undergo 
periodic division to give rise to TA cells (Figure 1.2).  TA cells low in the crypt undergo 
rapid division and eventually lose replicative potential and differentiate as they progress 
up the crypt. These cells are ultimately lost to the environment (36, 39).  
 As within the hair follicle, there is convincing evidence for an Lgr5+ non-label 
retaining population of colon stem cells additionally found at the base of the crypt (25).  
While the LRCs reside at the +4 population, Lgr5 cells are observed as slender wedge 
shaped cells at the +2 position.  Again, the exact relationship between the LRCs and the 
Lgr5+ cells is yet to be fully explored and more data into the lineage potential of both of 
these cell populations is needed to form a cohesive model.   
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Figure 1.2:  Colon crypt structure 
The colon is organized into crypt structures arranged hierarchically.  Two stem cell 
populations, Lrg5 cells at the base (pink) and cells at the +4 position (red), asymmetrically 
divide to self-renew and produce transit amplifying cells (orange).  Located just up the crypt 
from the stem cells, transit amplifying cells rapidly proliferate to replace cells that are 
constantly lost to the environment at the top of the crypt.  As transit amplifying cells move 
up the crypt, they differentiate into cell types that take up nutrients, support stem cells, and 
protect against infection (blue, green, purple, and yellow). 
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 Since the early identification of colon and hair follicle slow-cycling stem cell 
populations, label-retaining techniques have been used to identify and validate putative  
stem cell populations in multiple epithelial tissues.  In the mammary gland, three separate 
label-retaining populations have been identified and proposed as possible stem cells.  In a 
study conducted by Welm et al., BrdU LRCs were stem cell antigen-1 positive (Sca1+) 
and enriched for the ability to form both ductal and alveolar cell types (22).  In contrast, 
Shackleton et al. identified a BrdU LRC population that was hematopoietic lineage 
negative and enriched by the marker combination CD29hiCD24+ that did not enrich for 
the Sca1+ cells (23).  Pece et al. used the lipophilic fluorescent dye PKH26 to identify a 
population of mammary LRCs that demonstrated increased in vitro sphere formation 
efficiency (40).  Pece et al. used this LRC population to create a human normal 
mammary gland stem cell signature (hNMSC) consisting of the markers 
CD49F/DNER/DLL1. These findings may suggest a stem cell hierarchy in which 
multiple layers of stem cells exist within the mammary gland (41). 
 In the brain, quiescent cells were able to generate spheres in vitro or repopulate 
the proliferating population in vivo, suggesting a stem cell phenotype for these quiescent 
cells (42).  Prostate slow-cycling LRCs located in the proximal ducts demonstrated high 
proliferative potential and the ability to reconstitute the prostate glandular structure in 
vitro.  This ability singles them out as stem cells over more rapidly cycling TA cells 
located at the distal region of the ducts (43).    Finally in the pancreas, characterization of 
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LRCs around the acini and ducts suggested a stem cell population by demonstrating 
increased activation in response to damage to form duct-like structures (44).   
 Combined, these studies demonstrate an important pattern of tissue organization 
that appears to maintain slow-cycling cells in multiple epithelial tissues.  Importantly, the 
existence of slow-cycling cell populations is linked with the stem cell phenotype.  
 
Cancer Induction from Adult Stem Cells 
 In the United States, half of all men and a third of women will develop cancer 
over their lifetime (45).  Cancer is essentially a disease of uncontrolled cell growth.  
Unlike healthy cells, cancer cells bypass death signals and continue to grow, potentially 
spreading from the tissue of origin to other tissues throughout the body through a process 
called metastasis.  As tumors grow, they disrupt normal tissue function, taking up 
valuable space and nutrients.  Traditional chemotherapeutic treatments of cancer rely on 
cytotoxic compounds that damage DNA during cell growth, preferentially targeting 
rapidly proliferating cells with the intention of inducing cell death.  In colorectal cancers 
and other epithelial tumors, as many as 75% of late stage tumors will become resistant to 
traditional chemotherapies (46).  Surviving tumor cells lead to recurrence of tumors that 
are often more aggressive. Ultimately, tumor cells prevent the healthy organs from 
functioning and kill the patient. 
 The development of cancer is a complex multi-step process that requires the 
accumulation of mutations resulting in a cell acquiring the essential hallmarks of cancer: 
evasion of apoptosis, self-sufficiency in growth signals, insensitivity to anti-growth 
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signals, invasive and metastatic abilities, limitless replicative potential, and sustained 
angiogenesis (47).  Over years or decades, long-lived stem cells have the opportunity to 
accumulate oncogenic mutations from common mutagenic sources like inflammation, 
radiation, chemicals, or infection (48, 49). Combined with inherent limitless replicative 
potential, it is hypothesized that mutated adult stems cells are transformed into the cells 
of origin for many cancers (Figure 1.3) (50, 51).  Like healthy adult stem cells, 
transformed stem cells are expected to be able to generate a form of TA cell that unlike 
healthy TA cells, would be oncogenic and capable of driving tumor heterogeneity (18, 
39). Transformed stem cells have been termed cancer stem cells (CSCs) and are defined 
as the fraction of cells within a tumor that are long lived, possess the potential to 
proliferate indefinitely, and can generate the heterogeneity of the original tumor (39, 52).  
CSCs are expected to utilize characteristics commonly found in stem cell populations 
such as differential metabolic activity, specific signaling pathway activity, and regulation 
of cell cycling characteristics, albeit with aberrant regulation (18, 53).  Importantly, CSCs 
that survive chemotherapy treatment could account for tumor recurrence as a result of 
reactivation of proliferation in surviving CSCs (54).  Traditional chemotherapy regimes 
target proliferating cells, potentially missing slower dividing CSCs that must be 
eradicated to provide long-term disease-free survival (55).  A better understanding of 
CSCs is essential in understanding the biological and clinical consequences of existing 
regimens and designing new therapies to improve patient outcome (53).   
 Current methods for isolation and study of CSCs rely on cell surface markers 
found to be enriched in populations with stem cell-like properties.  This technique was  
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Figure 1.3:  Tissue and tumor cell hierarchy 
Adult epithelial tissues are organized hierarchically, with slow-cycling stem cell 
populations located at the top (1).  Stem cells asymmetrically divide to give rise to a new 
stem cell and a rapidly dividing transit amplifying cell.  Transit amplifying cells undergo 
rapid proliferation, required to replace cells that are lost to the environment (2).  Transit 
amplifying cells eventually differentiate into the multiple lineages of the adult tissue (3).  
Cancer stem cell populations are derived from adult stem cell or early transit amplifying 
cells that acquire oncogenic mutations over the life of an individual (4).  These cancer 
stem cells likely maintain the slow-cycling phenotype of their adult tissue counterparts 
and produce rapidly proliferating oncogenic transit amplifying cells that drive tumor 
growth (5).  Tumor transit amplifying cells differentiate into the heterogeneous tumor 
cells identified in epithelial tumors (6).  
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first used by Bonnet and Dick in 1997 when they demonstrated that only cells positive for 
the membrane protein CD34 and negative for the membrane protein CD38 were capable 
of initiating human acute myeloid leukemia (AML) in immune compromised mouse 
models (56).  Since the work of these two pioneers, CSC populations have been identified  
in multiple epithelial cancers including the breast (52), prostate (57), pancreas (58), colon 
(59-61), ovaries (62), and brain (63).   
 Unfortunately, the use of CSC markers has not been without controversy.  One 
issue centers on inconsistencies and uncertainty of the functional implications of CSC 
markers.  This uncertainty is best exemplified by the use of the stem cell associated 
membrane protein CD133 in the identification of colon CSCs.  Shortly after Ricci-Vitiani 
et al. (2007) demonstrated the use of CD133 to identify CSCs in colon tumors, Shmelkov 
et al. demonstrated that CD133 expression was not restricted to colon CSCs, but that 
CD133 is expressed on differentiated colonic epithelium in both mice and humans (60, 
64).  These data suggest CD133 expressing cancer cells may not all be stem-like.  
Reasons behind these contradictions were explored by Kemper et al. who methodically 
evaluated the differing epitope between the CD133 antibodies used by both groups.  
Kemper et al. reached the conclusion that the CD133 antibody used by Ricci-Vitiani et 
al. recognized a differentially expressed form of CD133 protein (termed AC133) that is 
not recognized by the antibody used by Shmelkov et al (65).  It appears that CD133 
protein is expressed in all colon epithelium, but the CD133 antibody used by Ricci-
Vitiani et al. identifies an undetermined modification of the CD133 protein, specific for 
the CSC phenotype.  Furthermore, Kemper et al. were unable to determine the functional 
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significance of the differentially modified isoforms of CD133, highlighting the 
disconnection between marker status and functional implication.  Very little is known 
about the function of many of the proposed CSC markers, while even less is understood 
about how these relate to the CSC phenotype.  CD133 is implicated in pluripotency and 
differentiation, suggesting it may somehow regulate cancer differentiation (66).  Other 
proposed CSC markers like CD44 and aldehyde dehydrogenase (ALDH) are linked with 
apoptosis resistance and chemoresistance and are less clearly related to the CSC 
phenotype.  At best, markers must be viewed as only tools for stem cell enrichment, 
suggesting the need for a more functionally significant means of CSC identification (67).  
Given the similarities between normal adult stem cells and CSCs, regulation of self-
renewal and cycling speed is likely central to CSC pathology (53, 54). Targeting 
pathways that mediate stem cell quiescence is therefore an intriguing alternate method for 
functional identification of CSC populations. 
 
Quiescence and CSCs 
 If CSCs do originate from normal adult stem cells, then it is foreseeable that key 
stem cell regulatory traits are retained through the oncogenic transition; quiescence is 
potentially one of these traits.  Little research has been done to address how quiescence 
might play a role in CSC biology, but there are some indications that quiescent stem-like 
populations might contribute to tumor development.  In primary ovarian tumors, Gao et 
al. demonstrated that slow-cycling cells expressed stem cell-associated genes like nestin, 
oct4, and both notch1 and notch4 (62).  Low numbers of slowly proliferating cells were 
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shown to produce tumors in a xenograft model where bulk cells were found to be non-
tumorigenic.  These data implicate a link between quiescence and ovarian tumor CSCs. 
 Pece and colleagues also observed a link between CSCs and quiescence in breast 
tumors (40).  Using the hNMSC signature associated with normal slow-cycling mammary 
cells discussed earlier, Pece et al. turned their attention to the analysis of primary breast 
tumors. They found that the hNMSC signature was more commonly found in grade 3 
tumors over that of grade 1.  When grade 1 and grade 3 mammospheres were analyzed 
for PKH26 label retaining cells, both populations were found to retain label, with grade 3 
tumors demonstrating a higher percentage. These data suggest an increase in slow-
cycling stem-like cells as tumors progress.  When evaluated for tumorgenicity, breast 
tumor cells positive for the hNMSC signature were more efficient at forming in vitro 
spheres and in vivo xenograft tumors than those cells lacking the hNMSC signature.   
 Cultured cancer cell lines are often used to study signaling pathways, invasion, 
migration and apoptosis, but are rarely thought of as candidates for CSC studies.  Many 
of the most widely used cell lines have been in passage for years, are perceived to be 
homogeneous, and change characteristics based on alterations in culture conditions.  
Therefore, cultured cell line studies assessing CSC characteristics must be evaluated 
critically, data interpreted within the context of the experimental parameters, and results 
confirmed under biologically relevant conditions.  Still, interesting work in the cultured 
breast tumor lines like MCF10A, MCF7, SUM149, SUM159, SUM1315 and 
MDA.MB.231 suggests that these lines may not be as homogenous as once thought.  
Cells expressing the marker combination CD44+/CD24/ESA+ within these lines were 
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found to contain the ability to self-renew, to reconstitute the parental line, and to be up to 
90% label retaining (68).  Additionally, the CD44+/CD24/ESA+ cells within these 
cultures were found to consistently produce tumors with as few as 1,000 cells, compared 
to unsorted cell lines that only consistently produced tumors with ten times as many cells.  
While these data appear to support a CSC phenotype, other researchers have 
demonstrated that single cell cloning some of these cell lines resulted in varied metastatic 
potential and protein expression within clone outgrowths, suggesting that tumor 
propagating cells within these cell lines may not be uniform in outgrowth potential (69, 
70).  Combined, these data suggest that while tumor-initiating potential may be restricted 
to a subset of cells, the tumor propagating phenotype may not be the result of a single 
CSC population atop a tumor cell hierarchy.  Future work will need to determine if these 
differences are the result of a single population responding to stimuli in multiple ways, or 
truly different cell types.  Importantly, these data demonstrate that popular cell lines are 
not homogeneous and add validity to future study of quiescent cells and their relationship 
to potential CSCs within these lines.   
 Additional connections between quiescence and CSCs was explored in the work 
conducted by Roesch et al. in melanoma (71).  This group found that primary melanoma 
cell lines contained a PKH26 label retaining population that was almost specifically 
identified by the H3K4 demethylase JARID1B.  This population of cells was found to 
incorporate BrdU more slowly, retain it for a longer period of time, lack staining for the 
proliferation marker Ki67, and have a doubling time of up to 4 weeks in vitro.  When 
EGFP was placed under the control of the JARID1B promoter, GFP+ cells demonstrated 
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increased sphere forming ability in vitro, suggesting increased CSC properties within 
these cells.  Interestingly, in vivo GFP+ cells did not show increased tumor initiating 
abilities over GFP cells.  These contrasting data highlight disparities between in vitro 
and in vivo culture systems and their ability to conclusively delineate the CSC phenotype.  
While these data may indicate that quiescent cells within an in vivo environment may not 
be enriched for the CSC phenotype, it is also possible that Roesch and colleagues are 
correct when they propose that the xenograft growth assays may better measure reaction 
to host-derived environments and the loss of tumor growth rather than tumor initiation 
potential.   
 The most direct evidence to date for quiescence playing a role in CSCs came from 
a study conducted by Dembinski and Krauss (72).  In this study Vybrant® DiI cell-
labeling solution was used to label pancreatic adenocarcinoma cells and conduct cancer 
stem cell studies on label-retaining cells that had been sorted by flow cytometry.  DiI 
label-retaining slow-cycling cells (DiI+/SCCs) comprised ~3% of total cell number.  
Interestingly, LRCs also exhibited an elongated fibroblast shape and an increase in the 
epithelial-mesenchymal transition (EMT) markers vimentin, snail, and twist. A 
fibroblast-like CSC is consistent with evidence demonstrating an increase in stem-like 
properties in cells that have undergone an EMT (73).  Importantly, this EMT has 
implications for progression towards metastatic abilities, allowing for tumor cell 
dissemination throughout the body.  Furthermore, sorted DiI+/SCCs demonstrated a 2.5-
10-fold increase in soft agar colony forming ability, two-fold increase in invasive 
potential, and more than a ten-fold increase in xenograft formation over non-label 
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retaining cells.  Combined, these data suggest that DiI+/SCCs represent an enriched slow-
cycling CSC population.  When assessed for common CSC marker status, DiI+/SCCs 
only partially overlapped with CD24+/CD44+ and CD133+ populations.  These data 
suggest the slow-cycling phenotype may not be associated with traditional CSC markers 
and highlight the critical importance for functional identification and characterization. 
 Like the melanoma study by Roesch et al. (71), Dembinski and Krauss’s study 
also indicated the ability for LRCs to produce non-LRCs and surprisingly also for non-
LRCs to produce LRCs, suggesting two possibilities: 1) that the true unknown CSC 
population is favored in the LRCs, but also found in the non-LRCs and can therefore give 
rise to both populations, or 2) that there exists a dynamic relationship in LRC-CSC 
populations that is context dependent and allows for inter-conversion between the two 
states.  The Dembinski and Krauss study argues a dynamic population of CSCs that 
might coincide with an EMT.  EMT plays a central role in embryogenesis and mesoderm 
differentiation into multiple tissue types during development while also having important 
implications for metastasis in the cancer setting (73).  The emergence of embryonic stem 
cell-associated genes like nanog, oct4, sox2, and c-myc in high grade undifferentiated 
cancers suggests that aberrant regulation of EMT and other early development pathways 
might be playing a role in CSC characteristics (74).  These data provide further evidence 
to support a dynamic slow-cycling stem-like model for many types of cancer.  
 
Quiescence and Resistance to Chemotherapy 
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 Tumors from different patients in the same organ are likely to have undergone 
different oncogenic transitions, leading to a diversity of possible regulatory mechanisms 
and pathway activities that might be contributing to the survival of a specific cancer.  
While broad patterns like the dysregulation of the stem-cell associated Wnt pathway in 
colon carcinomas are commonly observed, the secondary mutations that may accompany 
these cancers could be vastly different and contribute to survival in different ways (75).   
Even within the same tumor, different CSCs accumulate unique mutations that provide 
added resistance to chemotherapy, and pass these mutations on to daughter cells.  
Considering the vast differences in tumorigenesis and heterogeneity within a tumor, it is 
not surprising that the exact contributors to chemotherapy resistance and consequently 
which patients will respond optimally to chemotherapy are not well understood.  It has 
been proposed that variations in cell cycle-control, anti-apoptotic proteins, increased 
DNA damage repair capacity, up-regulation of cellular pumps, and increased metabolic 
activity may all play important roles in chemotherapy resistance (39, 76-79).   
 Conventional chemotherapies and radiotherapies target proliferating cells and 
require active cycling for induction of apoptosis.  The slow-cycling nature of many adult 
stem cell pools is therefore an inherent mechanism for resistance and cell survival in 
response to conventional therapies.  In the hematopoietic system, normal hematopoietic 
stem cells (HSCs) contain high levels of the CKI p21 (5).  When treated with the 
commonly used pyrimidine synthesis inhibitor 5-fluorouracil (5-FU), mice that were p21 
deficient had a significant decrease in cobblestone area-forming stem cells compared to 
normal p21 expressing wild type mice.  In the brain, Morshead et al. demonstrated that 
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high doses of tritiated thymidine (3H-TdR) killed the constitutively proliferating cells in 
the adult mouse forebrain, but had no effect on quiescent stem cell ability to survive and 
generate spheres when plated in vitro following treatment (42).  These data support a 
model in which slow-cycling mouse forebrain stem cells are able to survive and re-enter 
the cell cycle to allow for regeneration of the damaged tissue.  A similar pattern of stem 
cell survival and regeneration was observed following treatment with the DNA 
intercalator doxorubicin in mouse intestine.  In this experiment, mice epithelial intestinal 
crypts demonstrated increased amounts of cell death via apoptosis in the +3-6 positions 
stem cell compartment and a parallel disappearance of mitotic activity (80).  This period 
of relatively non-existent mitotic activity was followed by stem cell re-entry into the cell 
cycle and tissue regeneration in the stem cell compartment.  Furthermore, colon stem cell 
survival during chemotherapy is aided by increased expression of BCL2 family members 
that inhibit apoptosis (81). In chemotherapy-induced alopecia, the rapidly dividing TA 
cells in the hair matrix undergo apoptosis, while the stem cells in the bulge region survive 
to regenerate the follicle after chemotherapy is withdrawn.  These data suggest a 
relationship between slow-cycling cell populations and the resistance phenotype. 
 Similar mechanisms for survival and self-renewal for CSCs are plausible in 
instances of tumor recurrence in human patients where cytotoxic agents kill proliferative 
cancer cells, leaving slow-cycling cells (39).  CSCs that survive chemotherapy would 
have the ability to re-enter the cell cycle and produce highly proliferative, rapidly 
dividing progenitor cells that can re-establish the tumor (Figure 1.4).  It is probable that 
successive cycles of chemotherapy would further promote tumor progression by inducing 
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Figure 1.4:  Cancer stem cells and recurrence 
Epithelial tumors are believed to be hierarchically arranged with slow-cycling stem-like 
cell populations (red), rapidly proliferating transit amplifying cells (yellow), and more 
differentiated bulk tumor cells (blue and green).  Traditional forms of chemotherapy 
preferentially proliferating tumor cells, killing transit amplifying cells and more 
differentiated cells while leaving stem-like cell populations alone.  At the cessation of 
chemotherapy treatment, stem-like cells re-enter the cell cycle and produce transit 
amplifying cells that continue to dive and differentiate, leading to tumor recurrence. 
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further mutation and eliminating lesser resistant adult stem cells, thereby creating the 
opportunity for transformation into therapy resistant CSCs that give rise to resistant off-
spring (53).   
 CSC populations in the colon, breast, ovaries, and pancreas have been shown to 
demonstrate the ability to survive double the level of therapies that kill rapidly 
proliferating bulk tumor cells (62, 72, 79, 82).  These data demonstrate how ineffective 
conventional therapies can be on slow-cycling cell populations and help to explain why 
tumors that seem to fully regress during treatment can recur.  Furthermore, they suggest a 
model in which single CSCs, undetectable with current diagnostic technology, survive 
chemotherapy or radiation and are able to re-enter the cell cycle and re-establish tumors 
(68, 83).  Even more devastating to the survival of patients may be the CSC response to 
stress from chemotherapy and radiotherapy.  Mouse ovarian CSCs have been 
demonstrated to undergo symmetric division during radiotherapy regimens, expanding 
the CSC pool and driving development of a more aggressive secondary tumor (84).  
Furthermore, these CSCs may be positively selected to produce chemotherapy resistant 
offspring, rendering the tumor unaffected by later rounds of treatment. 
 While quiescence is likely to contribute to the survival of CSCs in response to 
chemotherapy and radiation, slow cycling is likely to work in parallel with other systems 
to increase survival.  Msi1+ colon cancer cells are less sensitive to cytotoxic drugs due to 
increased expression and orchestration of anti-apoptotic mechanisms (85).  The 
expression of anti-apoptotic BCL2 family members is frequently seen in stem cell and 
CSC populations and contribute to cell survival during radiation and chemotherapy (76, 
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77).  BCL2 family members are divided into three groups: the multi-domain pro-
apoptotic group, the pro-apoptotic BH3-only group, and the anti-apoptotic group.  The 
multi-domain pro-apoptotic group (BAX and BAK) is localized to the mitochondrial 
membrane and contains three conserved α-helical domains (BH1, BH2, BH3) (86).  In 
response to death stimuli, these family members oligomerize and form pores that release 
pro-apoptotic factors like cytochrome c from the mitochondrial intermembrane space, 
driving apoptosis (87).   The anti-apoptotic group (Bcl-2, Bcl-X, Bcl-w) is also primarily 
localized to the mitochondrial membrane and contains an additional conserved α-helical 
domain (BH4) (86).  These anti-apoptotic family members inhibit apoptosis in response 
to cytotoxic insults by sequestering BAX and BAK and preventing pore formation, thus 
stabilizing the mitochondrial membrane and preventing release of cytochrome C (88).  In 
contrast, the BH3-only pro-apoptotic members are initially localized to the cytosol or 
cytoskeleton and contain only the BH3 conserved domain.  In response to death 
signaling, BH3-only family members localize to the mitochondrial membrane and 
interact with anti-apoptotic family members to inhibit their function (86).  This inhibition 
of function allows for BAX and BAK to oligomerize, driving pore formation and 
apoptosis.  In this manner, sensitivity and resistance to apoptosis is determined by the 
ratio of pro-apoptotic and anti-apoptotic family members.  By increasing expression of 
anti-apoptotic family members like BCL2, cells are more able to resist the apoptotic 
signaling induced by standard chemotherapy and radiation.  Combining increased BCL2 
anti-apoptotic signaling and a reduction in cytotoxic stress from slower cycling, may 
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provide a mechanism for CSC populations to achieve multi-fold resistance capabilities 
over bulk tumor cells. 
 Additional mechanisms for CSC survival include increased DNA damage repair, 
up-regulation of cellular pumps, and increased metabolic activity through proteins like 
ALDH (78, 79).  Although the quiescence contribution to these mechanisms of resistance 
is unclear, it is likely that reduced proliferative rate only adds to their effectiveness.  
Additional time in S or G2 phase of the cell cycle coupled with increased DNA repair 
protein activity may afford a survival advantage over bulk cells that continuously accrue 
DNA damage and ultimately are forced to undergo apoptosis.  Reduced cycling speed 
together with increased cellular pump activity would facilitate drug removal from CSCs, 
limiting overall cytotoxic effects.  Additionally, slower cycling would allow for increased 
metabolic activity of ALDH and other metabolic proteins over that of bulk cells.  
Importantly, there is no reason why combinations or all of these resistance mechanisms 
could not be playing a role in CSC survival.  Future therapies may need to address all 
these issues to be successful in complete tumor eradication.   
 
Quiescence Regulators as Potential Therapeutic Targets 
 Given the importance of quiescence in the CSC contribution to tumor progression 
and survival, understanding the mechanisms that govern quiescence will lead to the 
identification of novel targets to better eliminate slow-cycling CSC populations.  Much of 
our current understanding of the mechanisms controlling quiescence comes from studies 
using conditional induction of quiescence in normal adult fibroblasts.  The induction of 
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quiescence in fibroblasts is generally accomplished in one of three ways: mitogen 
deprivation, contact inhibition, or loss of adhesion.  Each method of inducing quiescence 
in fibroblasts appears to yield a different quiescent transcriptional program (30).  The 
three transcription programs overlap in differential expression of 131 genes that Coller et 
al. have designated as a “quiescence signature.” This signature is comprised of genes that 
regulate cell growth and division, suppress apoptosis and differentiation, and govern 
intercellular communication.  Down-regulated elements in the quiescence signature 
consist of genes associated with cell cycle progression including cyclin B1, cdc20, cul-1, 
and myc.  Up-regulated genes included important cell cycle regulators like p53 and cyclin 
D2.  Also up-regulated in this signature are regulators of key stem cell associated 
pathways including the Wnt pathway, the BMP pathway, and the Notch pathway.  Notch 
activation of the stem cell associated transcription regulator Hes1 is of particular interest 
as it has been shown to control reversibility of fibroblast quiescence by blocking 
differentiation and entry into irreversible cell cycle arrest (31).  Notch pathway activity is 
important in mammary gland development as well as the mammary CSC response 
immediately following irradiation, suggesting that the Notch pathway may be a potential 
target in CSCs (49, 89).  Importantly, each one of these dysregulated factors and 
pathways represents a potential therapeutic target that may help in elimination of CSC 
populations.  Inducing expression of down-regulated targets or decreasing activity of up-
regulated targets may prove an effective means of increasing susceptibility of slow-
cycling cancer cells.  Future studies evaluating the role and importance of each of these 
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factors will play an important part in the development of next generation drugs aimed at 
eliminating the CSC population. 
 Interestingly, there exists a fourth transcriptional program in fibroblasts induced 
by over-expression of CKIs like p21 and p16 (30).  The CKI p21 has been found to 
control entry into quiescence and maintenance of the quiescent state, allowing cells to 
activate a DNA damage-like response (90).  Additionally, maintenance of fibroblast 
quiescence has also been shown to be highly regulated by the Rb family members (91).  
Loss of Rb family members did not affect the ability of fibroblasts to enter G0, but these 
cells were unable to maintain the quiescent state.  While Rb loss is generally associated 
with the progression of cancer, retention of Rb in CSCs or contribution of other Rb 
family members may be important in CSC maintenance of quiescence and a potential 
target. 
 Developing and studying a quiescence signature in fibroblasts may be important 
in understanding regulation of the cell cycle, but the exact relevance to slow-cycling stem 
cell populations is not clear.  Primarily, quiescence fibroblast studies are conducted on 
large populations of fibroblasts under biologically stressful conditions like contact 
inhibition or serum starvation.  In contrast, individual stem cells and CSCs maintain 
quiescence while in contact with daughter cells and stromal layers and in the presence of 
normal mitogenic signals.  Additionally, sphere-forming assays commonly used for the 
identification of stem cells and CSCs rely specifically on proliferation under non-
adherent conditions.  If mitogen deprivation, loss of adhesion, and contact inhibition truly 
activate three different transcriptional programs in quiescent fibroblast populations, it is 
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possible that the transcriptional program facilitated by slow-cycling stem cells and CSCs 
may be very different.  
 Quiescence regulation of a stem cell population is most comprehensively 
understood in the hematopoietic system.  When compared to differentiated or cycling 
HSCs, quiescent HSCs were found to have up-regulated genes associated with cell cycle 
regulation, translation, RNA processing, and metabolic processes (92).  Down-regulated 
genes were generally associated with transcription factors, signaling proteins, cell cycle 
proteins, and inhibitors of cell cycle progression.   In line with these findings, the CKIs 
p21 and p57 were found to be necessary for quiescence and maintenance of the HSC 
pool.  Mice that are p21 null demonstrate an increase in the number of stem cells present 
and lose the ability to repopulate the bone marrow in serial transplant experiments, 
suggesting uncontrolled expansion and eventual exhaustion of the stem cell pool (5).  
Similar results were obtained in p57 knockout mice that demonstrated a loss of the HSC 
population and a reduction in self-renewal potential associated with a loss of quiescent 
cells (7).  Deregulation of the stem cell pool is likely due to p21 and p57 downstream 
effects on Rb family members, which play important roles in regulating E2F activity and 
G1/S transition.  Knockout of these Rb proteins resulted in hematopoietic progenitor 
G1/S transition and proliferation, leading to exhaustion of the proliferative potential, 
similar to that seen in p21 loss (32).  Importantly, if Rb family members play a similar 
role in tumors, combining drugs that target these proteins may push slow-cycling cancer 
cells into the proliferative pool, making them more susceptible to traditional 
chemotherapeutics. 
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 While p21 appears to play a role in adult neural stem cell regulation and 
maintenance, other factors have been shown to be important contributors to quiescent 
stem cell activation (Table 1.1) (6).  Occasional exit of neural stem cells from the 
quiescent state is important for proper tissue maintenance and may be controlled though 
Notch signaling via Hes1 oscillations (93).   Down-regulation of Hes1 in neural 
progenitor cells during G1 phase reduced repression of cyclin D, ngn2, and Dll1, 
activating Notch signaling and driving cell cycle progression and generation of neural 
progenitors.  Neural progenitors and neurons continue to retain low levels of Hes1 as they 
proliferate and differentiate. In neural stem cells, Hes1 expression and control of cyclin D 
and Notch signaling increase until subsequent G1 entry.  These data suggest that it may 
be possible or necessary to target specific pathways like Notch signaling in combination 
with chemotherapeutics to better target slow-cycling cell populations. 
 Signaling pathways with interactions to other CKIs also play important roles in 
quiescent adult stem cell regulation.  In mammary glands, the Hedgehog pathway 
component Bmi1 has been demonstrated to regulate stem cell self-renewal (94).   When 
injected into cleared mammary fat pads, Bmi1 over-expressing mammospheres were able 
to produce substantially more outgrowths than control mammospheres.  Bmi1 has been 
demonstrated to transcriptionally repress the p16 and p19, suggesting a role for Bmi1 in 
mammary stem cell cycle control and revealing Bmi1 activation as a potential tool during 
chemotherapy treatment.    
  Additional signaling pathways have been demonstrated to play important roles in 
stem cell quiescence, specifically the bone morphogenic pathway (BMP) in skin.  BMP  
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Table 1.1:  Major Quiescence Regulators 
Pathway Regulator 
Cell cycle p21, p16, p57, Rb, p35/CDK5 
Wnt B-catenin, APC 
Notch Hes1, Jagged 1 
BMP NFAT1c 
Hedghog Bmi1 
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and calcineurin signaling up-regulate the transcription factor NFAT1c that has been 
found to highly co-localize with stem cells in the hair follicle (95).  NFAT1c represses 
transcription of CDK4, stalling cells in G1/S phase and maintaining quiescence.  Loss of 
NFAT1c permits entry into the cell cycle, shortening the telogen phase and prompting 
aberrant entry into the anagen phase.  If expressed in tumors, targeting NFAT1c may 
increase CSC susceptibility to chemotherapy. 
 Combined, these data suggest important roles for various pathways in quiescence 
regulation and subsequently potential therapeutic targets.  Understanding the contribution 
of each of these pathways in regulating the slow-cycling cell phenotype in cancers will be 
important in determining which pathways and potentially individual substrates can be 
targeted to better eliminate these cells.   
 Interestingly, it may be possible to target multiple pathways and downstream 
signaling components all at once by targeting key regulators at the intersections of many 
of these pathways.  The p35/CDK5 complex appears to have functions related to many 
quiescence associated pathways and factors.  Besides interactions with p27 and p16, 
p35/CDK5 may further regulate the cell cycle through interactions with E2F and the Rb 
family.  The CDK5/p35 complex is able to bind the cell cycle driver E2F and sequester it, 
inhibiting activation of cell cycle gene promoters (14).  Additionally, phosphorylation of 
the Rb family of proteins may inhibit release from E2F with similar results (15).   
 Furthermore, the roles of p35/CDK5 in therapy resistance may go beyond the cell 
cycle to promote cell survival and cell metastasis.  Activation of the Erk pathway or 
direct binding of BCL2 family members by p35 has been demonstrated to stabilize BCL2 
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protein and increase anti-apoptotic signaling and cell survival (96, 97).  At the cell 
membrane, p35/CDK5 is able to regulate E-cadherin and β-catenin signaling, down-
regulating E-cadherin and freeing β-catenin to relocate into the nucleus to drive Wnt 
signaling and quiescent associated signaling (98, 99).  Consequently, the down-regulation 
of E-cadherin ties p35/CDK5 to cytoskeletal turnover, suggesting implications for 
increased migratory abilities and the EMT transition, further linking p35/CDK5 to the 
quiescent stem-cell phenotype (73, 100, 101).   
 Combined, these data suggest that p35/CDK5 has multiple links to control of 
slow-cycling cells in normal tissues.  Therapeutic targeting of p35/CDK5 in combination 
with chemotherapeutics is therefore likely to push slow-cycling cells into a more 
proliferative state by decreasing CKI activity or increasing E2F activity, making cells 
more susceptible to DNA damage.  Additionally, p35/CDK5 inhibition is likely to lead to 
increased BCL2 degradation and decrease anti-apoptotic signaling, reducing quiescent 
slow-cycling cell ability to resist apoptotic stimuli.  
 While significant advances are being made in understanding quiescence control in 
normal adult stem cell populations, much less is known about control of quiescent CSC 
populations.  Very few studies have been conducted specifically addressing control of 
quiescent CSCs, mostly likely due to the difficulty of isolating and analyzing pure CSC 
populations.  If CSCs are truly derived from adult stem cells, then it is possible that 
CDK5/p35, Hes1, p21, p16, p57, Rb family members, and NFAT1c play significant roles 
in CSC regulation. 
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  Cancers frequently have aberrant signaling in the Wnt and Notch self-renewal 
pathways that likely contribute to cell cycle control and differentiation.  Increased 
expression of Hes1 has been observed in ovarian, breast, and non-small cell lung 
carcinomas, suggesting active regulation of Notch signaling (31).  In melanoma, the 
slow-cycling cells identified by Roesch et al., repress notch signaling directly though 
JARID1B interaction with the Notch ligand Jagged 1 promoter, consequently reducing 
intracellular Notch and controlling proliferation (71).  Hes1 and Jagged1 may therefore 
be potential targets in future cancer treatments designed to target CSCs.  Targeted 
reduction of Hes1 would increase Notch signaling, driving CSCs to proliferate and 
exhaust their proliferative potential, making them more susceptible to conventional 
therapy.   
 In colon cancers, mutations in Adenomatous polyposis coli (APC) and β-catenin 
are considered to be a driving force behind transformation (39).  In the presence of Wnt 
signaling, β-catenin is no longer taken up by the APC-dependent degradation complex 
and translocates to the nucleus where it binds transcriptions factors to control expression 
of cell cycle target genes.  Loss of APC in crypt cells has been demonstrated to be an 
important step towards initiation of intestinal adenomas (102). Interestingly, cells 
expressing high Wnt downstream transcription factors in primary sphere cultures 
demonstrated increased clonogenicity and the generation of both cycling and non-cycling 
cells (103).  In tumors, these high Wnt expressing cells were located near stromal 
fibroblasts that provided signals to activate β-catenin dependent transcription.  
Furthermore, p35/CDK5 activity was linked to β-catenin and activation of Wnt signaling.  
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Similar p35/CDK5 activity may contribute to response to androgen signaling in prostate 
cancers in response to apoptotic stimuli (104, 105).  These data suggest targeting Wnt 
pathway regulators may represent a potential mechanism for limiting CSC expansion and 
preventing recurrence. 
 While p35/CDK5, p21, Notch, and Wnt signaling may provide tempting targets 
for the removal of CSCs, disruption of these pathways would require meticulous 
targeting of CSC or titration of inhibitors to act on CSCs but not normal stem cell 
populations.  Such treatments could severely weaken patients.  Additionally, improper 
application of cell cycle inhibitors may fuel tumor growth and aggressiveness.   The CDK 
inhibitor p21 acts as a tumor suppressor in dividing cells by protecting against genome 
instability and working with other tumor suppressors to subdue oncogenes (106, 107).  
Loss of p21 combined with chemical induction of carcinogenesis has demonstrated 
increased induction of tumors and increased aggressiveness in resulting tumors (108, 
109).  Combining widespread targeting of p21 or CKI regulators like p35/CDK5 with 
chemotherapy may have similar effects on tumors.  These data highlight the necessity to 
be able to target CSCs selectively when using CDK inhibitors and add to the challenges 
ahead in developing treatments to better eradiate CSCs.  
 
Remaining Questions 
 The limited data available on the regulation of slow-cycling cells equates to a 
poor understanding of the role that these cells may be playing in tumor progression and 
recurrence.  What little evidence there is suggests that the slow-cycling phenotype might 
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be an important factor in tumor cell survival after conventional therapy.  Our work 
focuses on the utilization of novel pulse chase techniques to verify the existence of slow-
cycling cancer cells.  Mechanistically, slow-cycling cancer cells suggest an inherent 
population of therapy resistant cells that, when coupled with increased DNA repair or 
anti-apoptosis signaling could explain the patterns of recurrence and acquired resistance 
currently observed in post-therapy cancer patients. We evaluate the tumor initiating 
capabilities and therapy susceptibility of these slow-cycling cell populations to determine 
if this proposed mechanism is scientifically supported.  Additionally, we begin to profile 
differences between slow-cycling cells and rapidly proliferating cells and evaluate the 
differentially regulated protein p35 for contribution to the therapy resistance phenotype.  
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Chapter II: 
Slow-cycling Therapy Resistant Cancer Cells 
 
Abstract 
 Tumor recurrence after chemotherapy is a major cause of patient morbidity and 
mortality.  Recurrences are thought to be secondary to small subsets of cancer cells that 
are better able to survive traditional forms of chemotherapy and thus drive tumor re-
growth.  The ability to isolate and better characterize these therapy resistant cells is 
critical for the future development of targeted therapies aimed at achieving more robust 
and long-lasting responses.  Using a novel application for the proliferation marker CFSE, 
we have identified a population of slow-cycling, label-retaining tumor cells in both in 
vitro sphere cultures and in vivo xenograft models.  Strikingly, label-retaining cells 
exhibit a multi-fold increase in ability to survive traditional forms of chemotherapy and 
re-enter the cell cycle.  Furthermore, we demonstrate the innovative application of CFSE 
to live sort slow-cycling tumor cells and validate their chemoresistance and tumorigenic 
potential.   
 
Introduction 
 The incidence of recurrence after treatment in patients with epithelial tumors is a 
major obstacle in developing truly curative treatments.  Although many Stage II colon 
cancer patients show initial responses to standard chemotherapies, five-year recurrence 
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rates can be as high as 25% (110).  In breast cancer patients, 15-year recurrence rates are 
as high as 20% (111).  While factors associated with recurrence (sizes, grade, etc.) can 
suggest which tumors are likely to recur, the inability to accurately predict recurrence risk 
can lead to both unnecessary and insufficient treatment.  It appears likely that subsets of 
tumor cells evade initial chemotherapy and survive to re-propagate the tumor (79, 112)
 Traditional chemotherapies like 5-fluorouracil (5-FU) and Oxaliplatin require 
active cycling cells to trigger cell death (112, 113).  Cells that are quiescent or cycling 
slowly are therefore less likely to be susceptible to these drugs, suggesting an inherent 
recurrence mechanism in which slow-cycling cells evade therapeutic agents and re-
propagate tumors.  Evidence for such chemo-resistance abilities is observed in normal 
skin tissue where more slowly dividing cells in the bulge survive chemotherapy to 
regenerate the hair follicle (114).  In the mouse forebrain, high doses of tritiated 
thymidine (3H-TdR) kill constitutively proliferating cells, but have no effect on quiescent 
cells (42).   
   Similar to adult tissues, slow-cycling populations of cells have been identified in 
cancer tissues.  Roesch et al. demonstrated that primary melanoma cell lines contain a 
PKH26 label retaining population that has a doubling time of four weeks (71).  Using the 
same PKH dye, Kusumbe and Bapat demonstrated the existence of a slow-cycling 
population of cells in ovarian cancer (115).  Dembinski and Krauss used Vybrant® DiI to 
demonstrate a pancreatic adenocarcinoma slow-cycling cell population (72).  Even cell 
lines grown for years in vitro, like MDA.MB.231, have been found to contain label-
retaining cell populations (68).  The contribution that slow-cycling populations play in 
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chemotherapy resistance is not well studied and it is unclear if this characteristic may be 
a significant factor in tumor recurrence.  
 In this study, we use an innovative application for the cell tracing dye CFSE 
(carboxyfluorescein diacetate succinimidyl ester) to identify and isolate slow-cycling 
label retaining cells in both commonly used colon and breast tumor cell lines, as well as a 
primary human breast tumor.  We demonstrate that these slow-cycling cells are 
tumorigenic and more resistant to traditional chemotherapies than rapidly dividing cells.  
Importantly, slow-cycling cells survive treatment and demonstrate active DNA synthesis 
after the removal of chemotherapy drugs, suggesting that they may drive recurrence in 
the clinical setting.  
 
Results 
Detection of In vitro and In vivo Label Retaining Cells 
 To identify slow-cycling cancer cells, we developed a novel pulse/chase protocol 
utilizing the cell trace compound CFSE.  Initially, CFSE is membrane permeable and 
non-fluorescent (Figure 2.1A).  Upon entry into cells, two acetate groups on CFSE are 
cleaved by endogenous esterases and the compound becomes fluorescent under light 
stimulation.  Cleavage of the acetate groups additionally allows for binding of the 
compound to amine groups on protein, trapping CFSE within cells.  In rapidly 
proliferating cells, CFSE label is divided evenly between daughter cells, decreasing label 
intensity over successive divisions (Figure 2.1B).  In contrast, slow-cycling cells over the  
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Figure 2.1:  CFSE and label dilution 
(A) Carboxyfluorescein diacetate succinimidyl ester (CFSE) is initially non-fluorescent 
and membrane permeable.  Upon entry into the cell, the acetate groups are cleaved by 
endogenous esterases and the compound becomes fluorescent green under stimulation.  
Cleavage of CFSE allows for binding of the compound to amine groups found on 
proteins, trapping the compound within the cell.  (B) In rapidly proliferating cells, CFSE 
is divided evenly into daughter cells during division.  Over multiple divisions, CFSE is 
diluted out to low or undetectable levels.  In contrast, slow-cycling cells over the same 
period do not divide as frequently.  When they do divide, asymmetric divisions create 
one daughter cell that maintains the slow-cycling phenotype and one daughter cell that 
rapidly proliferates to dilute out the label.  Over time, populations of mixed slow-
cycling label retaining cells and dark rapidly proliferating cells are established.   
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same period of time undergo fewer divisions, retaining higher CFSE intensity, therefore 
distinguishing slow-cycling cells from their rapidly proliferating counterparts.   
 Because sphere cultures are considered to better retain properties of stem-like 
tumor cells, we used this system to determine if slow-cycling cells were present in the 
colon tumor line HCT116.  Like other groups, we found that in sphere media MDA-MB-
231 (MDA231) cells formed poorly proliferative, loosely associated clumps of cells that 
made pulse/chase growth assays impractical (116).  Therefore, MDA231 cells were 
grown as adherent cultures during evaluation for in vitro label-retaining cells (LRCs).  
MDA231 cultures or HCT116 spheres were digested into single cells and labeled with the 
fluorescent cell tracing dye CFSE.  Over the course of one week, dividing cells plated in 
media progressively dilute CFSE label between daughter cells, decreasing fluorescence 
intensity (Figure 2.2A).  At one week, a CFSE-high cell population was distinguishable 
from non/CFSE-low bulk cells by microscopy under both conditions (Figure 2.2B).  
When single cells were analyzed by flow cytometry, an average CFSE-high LRC 
population of 4.2± 2.1% was detected in HCT116 spheres and 0.99± 0.14% in MDA231 
adherent cultures (Figure 2.2C).  Using the mean CFSE intensity to compare CFSE-low 
cells (mean CFSE = 26.8) to CFSE-high cells (black box, mean CFSE = 227), HCT116 
CFSE-high cells were approximately 3 cell divisions behind non/low-labeled bulk cells 
(Figure 2.2C) indicating a distinct population of slowly dividing cells.  Cell cycle 
analysis of HCT116 CFSE-high spheres revealed a 2-fold increase in G2/M phase cells 
when compared to total cells (Figure 2.2D) suggesting an extended G2/M phase or arrest. 
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Figure 2.2:  In vitro identification of label retaining cells 
(A) Flow cytometry plot demonstrating HCT116 sphere dilution of CFSE over seven days.  
All HCT116 cells are intensely positive directly after labeling.  Over time, label is lost in 
rapidly proliferating cells, with a tail of more slowly cycling label-retaining cells visible 
after only three days. (B) Fluorescent and bright-field image overlay of HCT116 sphere 
cultures and MDA231 adherent cultures one week after CFSE labeling (scale bar = 100 µm) 
CFSE-high slow-cycling cells are identifiable in green within fields of dark bulk tumor 
cells. (C) Representative flow cytometry plot of digested HCT116 sphere cultures and 
MDA231 adherent cultures after seven days.  Black box depicts the approximate collection 
gate around the highest CFSE intense cells.  (D) Representative cell cycle profile of total 
HCT116 sphere cultures.  CFSE-low cells (Grey) and CFSE-high label retaining cells 
(Black) after one week and adjacent quantification bar graphs. 
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 We next used CFSE labeling to determine if slow-cycling cells were detectable in 
an in vivo system.  HCT116 and MDA231 cells were labeled with CFSE and injected 
sub-cutaneously or into the mammary fat pads, respectfully, of NOD/SCID mice.  After 
two weeks of growth, flow cytometry indicated a population of CFSE-high cells 
distinguishable from the bulk tumor cells: HCT116 with 11.6±2.9% and MDA231 with 
9.7%±3.5% CFSE-high cells (Figure 2.3).  To demonstrate that this was not limited to 
cell lines, we performed similar in vivo studies with a patient-derived primary breast 
tumor (2597T) that was serially passed in xenografts and digested to single cells before 
labeling and injection.  This primary breast tumor demonstrated an LRC content of 
5.3±0.8% (Figure 2.3A).  Using the proliferation wizard from the Modfit software 
package, we calculated that the top 5% CFSE intense cells have undergone at least 3-5 
fewer cell divisions than the bulk tumors cells in HCT116 xenografts (Figure 2.3B).    On 
frozen tissue sections of tumor xenografts, only a small number of scattered CFSE-high 
cells were detectable (Figure 2.3C), demonstrating the sensitivity of flow cytometric 
analysis over immunofluorescence microscopy for this system.  When analyzed for cell 
cycle stage, in vivo CFSE-high cell cycle profiles were similar to bulk tumor cells with 
only a slight enrichment for the G2/M phase (Figure 2.3D). 
 
Label Retaining Cells are Tumorigenic and Not Senescent 
 To assess the capacity of LRCs to contribute to tumor growth, we live-sorted 
pulse-chased HCT116 spheres (Figure 2.4A, Row1) and replated the CFSE-high cells.   
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Figure 2.3:  In vivo identification of label retaining cells 
(A) Composition of CFSE positive cells after 2 weeks of tumor growth in HCT116 
colon tumors, MDA231 breast tumors, and the primary breast sample 2597T tumors.  
(B) Representative flow cytometry plot of CFSE cell intensities for HCT116 tumor 
xenografts after two weeks growth.  White peak is the unanalyzed data according to 
CFSE intensity and cell number.  Grey peaks represent predicted dilution populations 
calculated by the proliferation wizard of the Modfit software package.  Six separate 
division peaks were calculated, with two small peaks of greatest CFSE intensity not 
visible.  Black bar approximates the gate used during live sorting to collect the highest 
5% intense cells.  (C) Fluorescent staining of HCT116, MDA231, and 2597T xenograft 
tumors counter stained with DAPI (blue).  Only rare cells retain a visible intensity of 
CFSE (green) while less intense cells are still detectable by flow cytometry (scale bar = 
100 µm).  (D) Cell cycle profiles for HCT116 xenografts. CFSE-low cells (Grey) and 
CFSE-high label retaining cells (Black) after two weeks and adjacent quantification bar 
graphs. 
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After one week, approximately 75% of CFSE-high cells had divided to form spheres 
(Figure 2.4A Row 2).  It is interesting to note that 25% of cells did not appear to divide  
and retained high levels of the CFSE label, suggesting that a population of LRCs may 
exhibit long-term cell cycle arrests. 
 To determine if in vivo derived LRCs are tumorigenic, CFSE pulse-chased 
HCT116 and 2597T primary breast tumors were digested after two weeks to single cells 
and live sorted for a maximum of 5% of the top CFSE-high cells. When 5,000 HCT116 
or 50,000 2597T CFSE-high cells were re-injected into 2 mice, large tumors were formed 
within two months.  Histologically, CFSE-high tumors were similar to tumors formed 
from the established parental cell line (Figure 2.4B).  Tumors were poorly differentiated, 
had little structure or organization, were densely packed with cuboidal tumor cells, had 
poor stromal or vascular presence, and had large necrotic centers. Cells from both tumors 
contained large nuclei with little cytoplasmic content and no cell polarity.  In the primary 
2597T breast line, CFSE-high tumors were also similar to the histology of the primary 
patient sample.  All tumors were poorly differentiated and contained loosely associated 
elongated spindle type cells as well as pockets of more densely packed cuboidal cells. 
Cells had irregularly shaped nuclei that were occasionally enlarged.  These tumors 
contained little vascular invasion or fibrotic scaring. 
  
LRCs are Enriched Following Chemotherapy 
 Slow-cycling label retaining cells in adult tissues have been demonstrated to 
survive chemotherapy better than other cells within the tissue (5, 80, 114).  To investigate  
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Figure 2.4:  Label retaining cells are colony forming and tumorigenic 
(A) HCT116 labeled spheres were digested after one-week growth (Row1) and live 
sorted for CFSE-high cells.  Fluorescent and bright-field imaging of representative 
HCT116 CFSE-high cells (green) after one-week (Row2).  (B) HCT116 or 2597T CFSE 
labeled tumors (Column1) were digested into single cells and live sorted for CFSE-high 
cells (EpCAM+ and Lin).  H&E images of CFSE-high xenograft growth (Column2).  
CFSE-high tumors are histologically similar to both parental tumor xenografts, and in 
the case of 2597T, similar to the primary patient tumor as well (Column3) (scale bar = 
100 µm). 
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if chemotherapy resistance is also a characteristic of our slow-cycling tumor cells, we 
CFSE labeled HCT116 cells and chased for one week in sphere media.  Single cell 
digests were then either plated in DMSO (vehicle control) or a chemotherapy reagent at a 
combined concentration to kill between 75% and 90% of cells and discern more resistant 
cells (Figure 2.5A).  After three days in culture, DMSO treated cells had expanded by 5-
fold, while Oxali (15%), 5FU (2.8%), and FOX (3.3%) treated cultures expectedly 
contained only a fraction of viable cells compared to DMSO controls (Figure 2.5B).  
When analyzed for CFSE, DMSO control samples demonstrated an expected decrease in 
CFSE content (15.2% to 7.1%) as these cells continued to proliferate.  Strikingly, Oxali, 
5FU, and FOX treated cells demonstrated 3.4, 6.7, and 7.1 fold increase in CFSE-high  
cell content respectively (Figure 2.5C). To determine if LRCs are capable of dividing 
after treatment, HCT116-FOX treated cultures were replated in sphere media containing 
BrdU.  After three days, 6.2% of total cells were BrdU+/CFSE-high cells suggesting 
approximately 10% of CFSE-high cells (6.2% of 59.1%) had undergone DNA replication 
and re-entered the cell cycle during this early post-chemotherapy recovery period (Figure 
2.5D).  Similar levels of CFSE-low cells were found to be BrdU+ as well, suggesting that 
surviving rapidly proliferating cells continued to proliferate following chemotherapy 
treatment. 
 To elucidate whether slow-cycling LRCs are chemo-resistant in vivo, CFSE 
labeled HCT116 cells were injected into NOD/SCID mice and allowed a 12 day chase 
before being placed on a FOX treatment regime (Figure 2.6A).  At the end of treatment, 
FOX treated tumors were significantly smaller in size (541mg) compared to DMSO  
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Figure 2.5:  In vitro label retaining cells demonstrate increased therapy resistance 
 (A) Timeline for in vitro HCT116 chemotherapy treatment experiments.  (B) Number of 
surviving cells after three days in the presence of DMSO, 2 µM Oxaliplatin (Oxali), 250 
µM 5FU (5-Fluorouracil), or the combination of Oxali and 5FU “FOX”.  (C) Percent 
CFSE positive cells after three days in the presence of drug.  Oxali, 5FU, and FOX treated 
samples are significantly enriched over DMSO treated samples (n = 3, *p = 0.01, **p < 
0.0001).  (D) Representative BrdU incorporation flow cytometry plots for FOX treated 
sphere cultures with single color controls. 
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treated controls (753 mg) (Figure 2.6B).  When analyzed for CFSE content, DMSO 
treated tumors averaged 5.3% CFSE-high cells while FOX treated tumors had a 
statistically significant increase in CFSE-high cells at 8.3% (Figure 2.6C).  When FOX 
treated tumors were pulsed with BrdU for four days, LRCs demonstrated the ability to 
cycle at least once over the time period through BrdU incorporation (Figure 2.6D) and a 
cell fraction within all stages of the cell cycle via DAPI stain (Figure 2.6E). Combined, 
these data demonstrate the ability for LRCs to re-enter the cell cycle and actively 
proliferate shortly after chemotherapy treatment.   
 
 Discussion 
 The use of CFSE to demonstrate the existence of slow-cycling label-retaining cell 
populations in cancer is divergent from the dye’s general use of short-term lineage 
tracing.  CFSE offers the distinctive ability to isolate and further characterize live, slow-
cycling cells apart from other label retaining methods, like BrdU, that require cell 
permeabilization.  Furthermore, CFSE dilution and retention relies on a functional 
cellular phenotype and is independent of protein markers with poorly understood 
functional contribution to cell dynamics.  We demonstrate the existence of a CFSE label-
retaining cell population in two epithelial tumors lines and one primary patient-derived 
tumor xenograft.  Slow-cycling populations of cells have been found in the normal colon 
(36)  and normal breast tissues (22, 23, 40), suggesting that this characteristic may be 
carried over from their tissues of origin and serve an important functional role in tissue 
longevity. 
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Figure 2.6:  In vivo label retaining cells demonstrate increased therapy resistance 
(A) Timeline for in vivo HCT116 xenograft treatment regime.  (B) Tumor masses at the 
end of treatment for DMSO (n=12) and FOX (n=8) (** p< 0.01)  (C) CFSE composition 
for DMSO and FOX treated tumors (* p = 0.045) (D) Representative BrdU incorporation 
flow cytometry plots for FOX treated tumors pulsed with BrdU.  CFSE-high cells 
incorporated approximately equal amounts of BrdU as CFSE-low.  (E) Representative 
DAPI derived cell cycle profiles for FOX. 
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 Importantly, the populations of LRCs that we identified both in vitro and in vivo 
are capable of re-activation.  While it is conceivable that a population of cells that enter a 
senescent state post-labeling would retain label, the identified LRCs are capable of 
division when live sorted and replated in sphere media and can regenerate tumors in vivo.  
Taken together, these data suggest that CFSE-high LRCs are capable of driving tumor 
formation and re-growth in a clinical setting.  
 The observed enrichment of LRCs after chemotherapy requires either the 
preferential expansion of the LRC pool or a reduction of the non-label retaining bulk 
cells.  Back calculations of the in vitro treated DMSO population suggests an increase in 
absolute LRC number from ~30,000 to ~80,000, due to LRC proliferation which 
generates partially-labeled daughters.  However, this expansion alone cannot account for 
the significant increase in overall LRC composition. In addition, the significant 
difference in survival between Oxaliplatin-treated samples and 5FU/FOX-treated samples 
further supports the concept of LRC enrichment due to increased chemotherapy 
resistance.  Oxaliplatin had an insignificant overall kill rate and only modest LRC 
enrichment, while 5FU killed a majority of cells and demonstrated a more profound LRC 
enrichment (Figure 2.5). These data indicate that LRCs are better able to survive standard 
chemotherapy treatments and their enrichment is related to chemotherapeutic efficiency 
of killing non-label retaining bulk cells. 
 In vivo, we see a similar pattern where treatment with clinically relevant 
concentrations of FOX resulted in modest de-bulking of tumors, corresponding with only 
modest LRC enrichment (Figure 2.6).  Unfortunately, increasing drug concentrations or 
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decreasing time between injections proved fatal for a high percentage of mice and 
hampered our ability to determine if a more profound de-bulking of tumor cells would 
lead to greater fold LRC enrichment.  
 In in vitro spheres, HCT116 LRCs were enriched for cells in the G2/M phases of 
the cell cycle (Figure 2.2C).  Other groups have associated a G2/M phase arrest with 
increased resistance to multiple forms of chemotherapy and a propensity to evade 
apoptosis (117, 118).  It is therefore likely that the G2/M arrest observed in our LRCs is a 
contributing factor to the observed enrichment; perhaps by extending the time for repair 
or providing the means to evade apoptotic signals.  It is also possible that simply arresting 
in the G2/M state primes LRCs to better respond to cellular stresses and apoptotic 
signaling that results from therapeutic treatment.  
 While the ability of cancer cells to survive chemotherapy is important, clinically 
significant cells must also be capable of proliferation to stimulate tumor recurrence.  
Therefore, it is important to establish that CFSE-high LRCs are not avoiding the 
cytotoxic effects of FOX treatment by entering a permanently non-dividing state.  Both in 
vitro and in vivo, a subset of FOX treated LRCs were able to incorporate BrdU shortly 
after removal of FOX (Figure 2.5D & 2.6D), demonstrating the capacity of LRCs to 
actively proliferate and conceivably contribute to tumor recurrence after treatment.  This 
suggests that slow-cycling cells are activated after chemotherapy withdrawal to re-
propagate the tumor. 
 Given the therapy resistant and tumorigenic properties of label retaining cells, it is 
conceivable to conclude an association between slow-cycling cells and cancer stem cells 
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(CSCs).  The concept that subsets of tumor cells have increased capacity for tumor 
propagation in mice is still evolving. For instance, in some models of cancer stem cells 
(such as melanoma) most if not all cells are tumorigenic (119), while in other system 
(such as in colon cancer) surface markers have been shown to be non-specific, 
with marker positive and negative cells showing tumorigenicity (60, 64). Evidence from 
other groups in ovarian tumors, mammary tumors, and melanoma cell lines has 
demonstrated a connection between the slow-cycling phenotype and identified CSCs 
populations (40, 62, 71).  However, we believe our findings to be biologically and 
clinically significant, independent of a cancer stem cell model.  Given the possibility that 
most or all cancer cells could be tumorigenic, we identify a subset of slow-cycling cells 
that is better able to survive treatment, and thus more capable of leading to tumor 
recurrence. 
  In summary, we propose a model in which a subset of slow-cycling tumor cells 
have enhanced chemo-resistance and proliferate after chemotherapy withdrawal to allow 
for tumor recurrence in a clinical setting.  Furthermore, this study details an innovative 
method to isolate, enrich, and better characterize a population of live therapy resistant 
cells in both in vitro cultures an in vivo xenografts.  This work should allow for future 
live enrichment and better characterization of chemotherapy resistant populations in order 
to develop more targeted therapies. 
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Chapter III:   
Regulation of Slow-cycling Cancer Cells by p35 
 
Abstract 
 The existence of chemotherapy-resistant slow-cycling cancer cells is a major 
challenge in limiting tumor recurrence and ultimately improving patient survival.  A 
better understanding of the mechanisms that regulate the slow-cycling therapy-resistant 
phenotype will allow for the development of drugs that better target these cells.  We 
identify the CDK5 activator, p35, as differentially regulated in slow-cycling cancer cells.  
Over-expression of p35 leads to increased chemotherapy resistance and increased 
staining for the anti-apoptotic factor BCL2.  Additionally, increased expression of p35 
was observed following chemotherapy in rectal cancer samples.  These data suggest a 
model in which slow-cycling cancer cells utilize increased expression of p35 to regulate 
cycling speed and stabilize BCL2 expression, thus increasing chemotherapy resistance 
and promoting tumor recurrence.  
 
Introduction 
 Tumor recurrence in epithelial tumors like those of the colon and breast is a major 
obstacle to achieving complete remissions in cancer patients.  In its most advanced stages 
of progression, colorectal cancers can have recurrence rates as high as 75% (46).  
Compounding the issue, recurrent tumors are often more aggressive and resistant to 
previously successful chemotherapeutic treatments.  A better understanding of slow-
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cycling cancer cells is critical for targeting these therapy resistant populations and 
achieving better patient outcomes. 
 It is believed that small populations of stem-like cancer cells evade the cytotoxic 
effects of traditional forms of chemotherapy and drive tumor recurrence.  These stem-like 
cancer cells are thought to originally develop from adult tissue stem/progenitor cells 
given similar characteristics between the two populations (50, 51).  If this is true, the 
chemotherapy resistance and regulatory mechanisms found in adult stem cells may be 
carried over to stem-like cancer cells. 
 Control of cell cycling speed is one likely mechanism found in both adult stem 
cells and stem-like cancer cells.  Traditional forms of chemotherapy target actively 
proliferating cells by inducing DNA damage and apoptotic signaling.  Therefore, cells 
with reduced cycling speeds or infrequent divisions would have an inherent mechanism 
of resistance to these types of therapies.  This concept is supported by experiments that 
demonstrate populations of slow-cycling adult stem cells with greater resistance to 
cytotoxic effects of chemotherapy compared to more rapidly proliferating cells (5, 42). 
 Previous work from our lab has demonstrated that the slow-cycling phenotype of 
normal adult epithelial stem cells may be present in slow-cycling cancer cells.  We have 
demonstrated the existence of colony-forming slow-cycling populations within in vitro 
sphere cultures and in vivo xenografts (120).  Furthermore, these slow-cycling cells are 
more resistant than rapidly proliferating cells to traditional forms of chemotherapy, and 
are able to re-enter the cell cycle following the cessation of treatment.  This work 
suggests slow-cycling cells may be better able to resist chemotherapy and ultimately 
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provide a means for tumor recurrence.  Identifying and understanding genes that control 
cycling speed and regulate resistance should lead to the development of drugs to better 
eliminate these cells. 
 Interestingly, evidence suggests that the poorly understood CDK5 regulator, p35 
(CDK5R1), may be one of these therapeutic targets.  Most intensively studied in neuron 
progenitor cells, p35 acts in a similar manner to other cyclins by binding and activating a 
member of the CDK family, specifically CDK5 (121).  Binding affinity, protein stability, 
and even protein targets of CDK5 are dependent on binding either a 35 kD form of p35 or 
the cleaved 25 kD form (14).  Unlike other cyclin/CDK complexes, the p35/CDK5 
complex does not play an active role in driving the cell cycle forward, but instead may 
have broad alternate functions related to suppressing cell cycling, migration, and survival 
as well as the development of Alzheimer’s disease (11). 
 In patients with Alzheimer’s disease, dysregulation of p35/CDK5 levels leads to 
the development of neurofibrillary tangles that are believed to be a major factor in disease 
progression (122).  Knockout studies of p35 in mice produce neurons that fail to arrange 
cortical lamination correctly and migrate away from the niche, leading to seizures and 
adult lethality (123).  These studies suggest that regulation of migration is an important 
function of the p35/CDK5 complex.  Cellular migration is regulated by the p35/CDK 
complex through phosphorylation of the cytoskeletal protein Tau at the PHF-1 sites.  
PHF-1 phosphorylation leads to release of Tau from microtubules and cytoskeletal 
destabilization, allowing for microtubule turnover and cell migration (100, 101).  
Migration activity is further regulated by a CDK5-independent function of p35 that can 
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bind and target E-cadherin to lysosomes, increasing cell migration (98).  In complex, p35 
functions to phosphorylate β-catenin, altering binding to cadherins and other cell-to-cell 
interacting proteins, regulating cell adhesions, and opening the door for β-catenin to 
translocate into the nucleus and drive stem cell-associated Wnt signaling (99, 124).  
These functions help to regulate migration and stem cell activity in developing neurons 
and could play an important role in regulating similar functions in slow-cycling cancer 
cells.  Increases in p35 expression have been associated with meningioma progression 
with possible links to β-catenin localization and activation of Wnt signaling (125).   
 At present, the basic understanding about expression patterns and the role of 
p35/CDK5 in epithelial cancers remains unclear.  In prostate cancers, increased 
p35/CDK5 expression is linked to increased androgen receptor signaling and survival in 
response to certain forms of apoptotic stimuli (104, 105).  Apart from these tumors, 
p35/CDK activity has been demonstrated in other cancers including pancreatic (126), 
breast (127), and lung (128), although with the impact of this activation is yet to be fully 
explored.   
 Importantly, the p35/CDK5 complex may play a protective role in cellular 
responses to certain forms of apoptotic stimuli that signal through the mitochondrial 
apoptotic pathway.  Activation of p35/CDK5 by the mitochondrial apoptotic pathway has 
been demonstrated to increase signaling through the ERK pathway, leading to the 
phosphorylation and stabilization of BCL2 and increasing cell survival (96, 97).  
Additionally, Erb phosphorylation by p35/CDK5 may mediate neuronal survival by 
inducing Akt/PI3-kinase signaling (129).  Similar responses elicited in tumor cells 
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expressing p35/CDK5, may represent an important survival mechanism mediated by 
BCL2 stabilization. 
 Other protective functions of p35/CDK5 may relate to the ability of the complex 
to suppress cell cycle progression.  When bound to the 35 kD form of p35, CDK5 is able 
to complex with the cell cycle driver E2F.  This interaction inhibits the ability of E2F to 
bind and activate cell cycle gene promoters, providing neuronal protection from cell 
stress (14).  Additionally, evidence suggests that the p35/CDK5 complex can associate 
with the cycling dependent kinase inhibitor, p27 and the retinoblastoma protein (Rb) to 
suppress the cell cycle (15).  If p35/CDK5 retains the ability to regulate the cell cycle in 
tumor cells, it may provide a mechanism to resist synthesis-dependent DNA damage and 
apoptotic signaling during chemotherapy. 
 Here we demonstrate that the CDK5 regulator, p35, is consistently up-regulated in 
slow-cycling cancer cells grown in culture or as tumor xenografts. Strikingly, 
manipulations of p35 levels correlate with cell survival following treatment with 
traditional chemotherapy drugs.   Immunofluorescence imaging suggests this therapy 
resistance may be due in part to interactions between p35 and the pro-survival protein 
BCL2.  Finally, we demonstrate clinical evidence for a protective role of p35 by 
examining pre-chemotherapy and post-chemotherapy matched patient samples of rectal 
cancer for p35 expression. 
 
Results 
Bcl2 and p35 are Up-regulated in Slow-cycling Cancer Cells 
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 A deeper understanding of the mechanisms that lead to therapy resistance in slow-
cycling cancer cell populations will lead to the development of better treatments and 
increased patient survival.  To identify slow-cycling cancer cells, our lab utilizes a CFSE 
based pulse/chase technique to identify slow-cycling tumor cells (Figure 3.1).  Cells were 
labeled with CFSE and plated in an in vitro B27 based non-adherent sphere media or 
injected in vivo into the mammary fat pads of immune compromised mice (Figure 3.1 A).  
After a growth period in which rapidly proliferating cells dilute label among daughter 
cells, spheres or tumors are digested into single cells and live sorted into CFSE-high and 
CFSE-low cells for characterization and further analysis (Figure 3.1B).  Under 
fluorescent microscopy, single CFSE label retaining cells are visible within spheres 
(Figure 3.1 C). 
 Previous work from our laboratory has demonstrated increased resistance to 
traditional forms of chemotherapy in CFSE-high slow-cycling cancer cells (Chapter 2) 
(120).  To determine important signaling pathway regulators that allow slow-cycling 
cancer cells to better evade the cytotoxicity of chemotherapy, we designed a quantitative 
PCR (qPCR) array to assess differences in mRNA expression for 93 cell cycle regulators, 
stem cell related genes, and survival associated genes.  Using Fluorescence Activated 
Cell Sorting (FACS) we live sorted CFSE-high and CFSE-low cells from the colon tumor 
line HCT116 (in vitro n=2, in vivo n=3), the breast tumor line MDA-MB-231(n=3), two 
primary patient derived colon tumors (designated 48116 and 2953T, n=1 for each), and 
one primary patient derived breast tumor (designated 2597T, n=1), isolated mRNA, and 
used the subsequent cDNA to perform the qPCR array.  Although tumor material limited  
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Figure 3.1:  Identification of slow-cycling cancer cells 
(A) To identify slow-cycling cancer cells, cultured cell lines or tumors are digested into 
single cells and then label CFSE.  In vitro analysis is performed by replating cells in 
sphere media while in vivo analysis is done by mixing cells with matrigel and injecting 
into the mammary fat pads of mice.  During a chase period, cell populations expand with 
rapidly proliferating cells diluting label and slow-cycling cells retaining label.  At the end 
of the chase period, spheres and tumors are for ready assay to characterize slow-cycling 
cancer cells. (B) Representative flow cytometry plot for HCT116 in vitro sphere cultures 
after seven days of chase.  CFSE-high cells (green box) are identified as the cell 
population that is approximately ten-fold higher in CFSE intensity than CFSE-low cells 
(blue box). (C) Representative bright-field and fluorescent overlay of an HCT116 sphere 
after seven days pulse/chase with CFSE.  Individual CFSE retaining cells (white arrows) 
are visible within the sphere. 
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primary tumor data to a single array, when comparing label-retaining cells to bulk tumor 
cells, label-retaining cells did consistently demonstrate greater than 2-fold increase in 
expression of the anti-apoptotic factor BCL2 and the CDK5 activator p35.  These 
differences were observed within not only tumors of the same tissue of origin, but for 
both tumor types (Table 3.1).  Interestingly, the array results did not suggest activation of 
any specific pathways like Notch or Wnt that might be tied with stem-ness, cycling 
speed, or cell survival (Table 3.1 and Appendix II).   Additionally, the array analysis did 
not suggest consistent differential regulation of known quiescence regulators such as 
CDKN1A (p21), CDKN2A (p16), or NFAT1c. 
 
Expression of p35 Regulates Cell Cycle Progression 
 Given the ability for p35 to slow the cell cycle of neuronal cells (14, 16), we 
explored what role p35 might play in the context of slow-cycling cancer cells.  First, we 
created puromyocin selected HCT116 cell lines stably expressing small hairpin RNAs 
(shRNAs) targeting p35 (constructs identified as shp35-G6 and shp35-G8).  We 
additionally created HCT116 cells transiently transfected with a p35 expression construct 
driven by the CMV promoter (identified as CMV-p35).  Analysis of p35 expression by 
qPCR indicated that with either clone of the p35-shRNA construct, transduced cells 
expressed approximately half the p35 transcripts as the control (Figure 3.2A).  After 
transfection with the over-expression construct, p35 was increased ~ 20 fold more 
transcript than empty vector transfected cells.  It is important to note that array data 
indicate a range of over-expression in slow-cycling cells from ~2-7 fold, suggesting that  
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Table 3.1:  BCL2 and p35 are up-regulated in slow-cycling cancer cells 
 HCT116 
in vitro 
HCT116 
in vivo 2953T 48116 MDA231 2597T 
BCL2 3.05 3.67 1.89 2.38 5.74 3.43 
CDKN1A 2.65 2.45 1.00 0.77 1.49 2.56 
CDKN2A 2.52 1.18 0.97 0.79 2.37 1.36 
NFAT1c 3.70 1.97 0.94 0.63 1.22 2.29 
NOTCH1 3.89 1.43 0.74 0.54 2.00 - 
NOTCH2 1.15 3.93 0.78 0.70 1.02 1.07 
p35 2.63 2.39 7.09 3.81 1.79 6.57 
WNT1 3.18 1.13 0.62 0.36 0.82 1.48 
Value indicate fold CFSE-high expression relative to CFSE-low 
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Figure 3.2:  p35 slows the cell cycle 
(A) HCT116 colon tumor cells were transduced with shRNA vectors targeting p35 (two 
different constructs G6 and G8) or transfected with a vector a CMV promoter driving 
p35 over-expression.  shp35 clones had approximately half the p35 transcript expression 
of shGFP controls.  CMV-p35 HCT116 cells had approximately 20-fold the p35 
transcript expression as empty vector transfected cells.  (B) Representative cell cycle 
analysis of shp35 HCT116 clones (blue and purple) compared to shGFP control cells 
(grey).  No difference was observed between the clones (n=2).  (C) Representative cell 
cycle analysis of CMV-p35 transfected cells (red) and untrasfected controls (grey).  
CMV-p35 expressing clones had fewer cells within S phase compared to controls (n=3). 
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a 20 fold increase in expression may be above physiological relevance and that potential 
off target effects may be possible. 
 When cell cycle analysis was performed on these populations, relative to the 
shGFP control, the loss of p35 did not significantly change the cell cycle profile (Figure 
3.2B).  In contrast, over expression of p35 shifted cells out of the S phase of the cell cycle 
and into the G0/G1 phase (Figure 3.2C). 
 
Expression of p35 Regulates Survival after Chemotherapy 
 We next explored the effect of p35 levels on the ability of cells to resist the 
cytotoxic effects of chemotherapy.  Using shp35 and CMV-p35 HCT116 clones, we 
plated single-cell suspensions in either DMSO or the drug combination of 250 µM 5-
Fluorouracil and 2 µM Oxaliplatin (FOX).  This drug combination is consistent with the 
standard of chemotherapy treatment for patients with colon carcinoma.  Compared to the 
shGFP control, shp35-expressing cells demonstrated increased cell death, with only half 
the number of cells surviving treatment (Figure 3.3).  In contrast, almost two-fold more 
cells survived chemotherapy in p35 over-expressing cells compared to empty vector 
controls.  This data suggests a protective role for p35 in response to traditional a form of 
chemotherapy in HCT116 colon tumor cells. 
 
Expression of p35 and Pathway Activity 
 Understanding the pathways controlled by p35 in slow-cycling cells is an 
important step to determine how p35 might lead to increased therapy resistance and cell  
 75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3:  p35 regulates chemotherapy resistance 
HCT116 shp35 clone spheres and adherent CMV-35 clones were treated with DMSO 
control or FOX drug combination (250 µM 5FU and 2 µM Oxaliplatin) for three days.  
At the end of treatment, cultures were digested to single cells and counted for live cells 
via trypan blue staining.  Relative to shGFP control, both shp35 construct expressing 
cell lines had approximately half the surviving cells.  In contrast, CMV-p35 transfected 
cells had almost two-fold more surviving cells than CMV-empty control cells. 
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cycle control.   We first wanted to determine if p35 is binding to activate CDK5 or if it 
could be functioning independently of this complex.  To confirm that p35 does in fact 
bind to CDK5 in HCT116 tumor cells, we performed an immunoprecipitation (IP) with 
an antibody against CDK5 and probed for p35 by western blot (Figure 3.4A).  Compared 
to IgG controls, the full-length form of p35 was successfully pulled down.   This data 
confirms complex interaction between CDK5 and p35 and suggests that interaction is 
primarily with the full-length 35 kD form.   
 We next wanted to determine if we could detect differences in the presence and 
activation of p35/CDK5 targets when levels of p35 were altered.  Phosphorylation of Tau 
at both Ser-396 and Ser-404 are well established targets of p35/CDK5 and are recognized 
by the PHF-1 antibody (100).  When knockdown and over-expression clones were 
analyzed by western blot to look for changes in PHF-1 levels, we were unable to detect 
any significant change between the clones and relevant controls.  These data suggest that 
p35 may not act significantly on Tau in slow-cycling cancer cells (Figure 3.4B).  p35 is 
also know to play an important role in β-catenin phosphorylation and E-cadherin 
endocytosis, allowing for differentiating neuronal cell migration away from the niche 
(98).  Western blots revealed that levels of β-catenin and E-cadherin did not change 
between shp35 and CMV-p35 expression clones on a global scale.  These data suggest 
that p35 may not play a significant role in the regulation of β-catenin and E-cadherin 
protein levels within cancer cells.  Lastly, we looked for changes in BCL2 levels within 
our p35 clones.  As with Tau, β-catenin, and E-cadherin, we did not see any significant 
change in total protein level by western blot. 
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Figure 3.4:  p35 in cancer 
(A) Western blot probing for p35 following immunoprecipitation with anti-CDK5 
antibody in HCT116 cells.  CDK5 is able to pull down the 35 kD form of p35 but not 
the p25 kD form. (B) Western blot of HCT116 shp35 and CMV-p35 clones evaluating 
protein expression of potential p35 binding partners and targets.  No significant changes 
were observed in phosphorylation of PHF1 (p-tau), CDK5, BCL2, β-catenin, or E-
cadherin across all clones in relation to controls.  (C) Representative flow cytometry 
expression profile for HCT116 CMV-p35 transfected cell lines.  Expression of p35 is 
only highly up-regulated in 11.5 % of cells. (D)  p35 localization in transfected cells.  
Staining is in a lattice-like pattern consistent with cytoskeletal association.   
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 In contrast to the puromyocin selected shRNA clones, low transfection 
efficiencies of our CMV-p35 vector (~10%) may not sufficiently change p35 target levels 
on a culture wide scale (Figure 3.4C).   By immunofluorescent staining, CMV-p35 
expressing cells appeared to have p35 localized to both the cytoplasm and nucleus of the 
cell in patterns consistent with findings by other groups (Figure 3.4D) (96, 99, 128, 130).  
Staining for p35 within the cytoplasm was very intense, with lattice-like staining features 
that suggest association with the cytoskeleton.  Modest p35 nuclear staining was present, 
but was less intense than cytoplasmic staining, suggesting localization to the nucleus and 
the potential to regulate cell cycle progression as observed in our cell cycle profiles. 
 To evaluate the effect of p35 over-expression on potential p35 targets on a single 
cell scale, we performed immunofluorescent (IF) co-stains on CMV-p35 cells with anti-
p35 antibody and antibodies against β-catenin, E-cadherin, PHF-1, or BCL2.  IF staining 
did not result in any observable differences in the expression level or localization of the 
β-catenin or E-cadherin proteins when compared to adjacent non-transfected cells (Figure 
3.5 A and B).  These data support the western blot data and suggest that p35 may not 
have significant roles in β-catenin and E-cadherin localization or expression levels in 
slow-cycling cancer cells and may function in a context dependent manner unique from 
established functions in neuronal precursor cells.  
 To evaluate changes in phosphorylation of Tau Ser-396 and Ser-404 in p35 over-
expressing cells, we co-stained with both p35 and PHF-1 targeting antibodies. 
Surprisingly, PHF-1 positive staining cells were exclusively negative for p35 staining, 
suggesting that p35 may not act on Tau in slow-cycling cells (Figure 3.5 C).   
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Figure 3.5:  p35 target regulation 
Immunofluorescent staining of HCT116 CMV-p35 clones for p35 (green) and potential 
p35 targets (red) countered stained with DAPI (blue).  Cells expressing p35 (white 
arrows) did not demonstrate altered β-catenin (A) or E-cadherin (B) expression compared 
to untransfected cells.  (C) Expression of p35 also did not overlap with PHF1 staining (p-
tau).  (D) Cells positive for p35 staining have increased BCL2 puncta compared to 
adjacent untransfected cells.  
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 Most importantly, we co-stained CMV-p35 transfected cells with antibodies 
against BCL2 and p35.  In contrast to our western blot data, we observed increased 
punctal staining of BCL2 in a high percentage of cells over-expressing p35 (Figure 3.5 
D).  These data suggest that p35 may act through one of the mechanism reported by other 
groups to localize or stabilize BCL2 protein levels in slow-cycling cancer cells (15, 97).  
These findings also help to explain why western blots did not detect significant increase 
in BCL2 expression in CMV-p35 clones.  The increased expression of p35 in the 
relatively low percentage of transfected cells is likely not substantial enough to increase 
BCL2 protein expression in total culture lysates. 
 
Expression of p35 Increases after Chemotherapy in Primary Tumors 
 To determine whether p35 may play a role in therapy resistance in cancer patients, 
we obtained pre-chemotherapy treatment biopsies and post-chemotherapy treatment 
surgical samples from 20 patients with rectal tumors.  Rectal cancer patients receive very 
consistent therapeutic treatments, limiting potential discrepancies caused by differences 
in treatment protocols.  Additionally, the tissue structure of the rectum is similar to that of 
the colon and likely to utilize similar regulatory patterns that may be carried over into 
tumors.   
 Epithelial tumor glands and high nuclear to cytoplasmic ratio cells was readily 
apparent on pre-treatment biopsies (Row 1, Figure 3.6).  In contrast, post-chemotherapy 
epithelial tumor gland staining was greatly reduced, leaving isolated outgrowths of 
resistant tumor cells surrounded by fibrotic scar tissue (Black arrows, Figure 3.6).  When  
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Figure 3.6:  p35 expression increases post-chemotherapy in rectal cancers 
Pre-chemotherapy tumor biopsies and post-chemotherapy surgical samples were collected 
from 20 patients with rectal tumors.  H&E staining (Row 1) of pre-chemotherapy tumors 
(Column 1) demonstrates that tumors have a high quotient of epithelial cells (purple).  
Post-chemotherapy (Column 2), samples were primarily fibrotic (pink) due to scaring 
from treatment with only few outgrowths of surviving epithelial cells (black arrows).  
Immunohistochemical staining for p35 (Row 2) revealed the presence of rare p35 
expressing cells (red arrows) in pre-chemotherapy samples.  Prevalence of p35 positive 
cells increased in post-chemotherapy samples.  When counted and quantified across all 
samples, expression of p35 significantly increased post-chemotherapy (15.23 % to 23.46 
%, p = 0.026). 
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tumor sections were immunohistochemically stained for p35, rare cells were positive for 
cytoplasmic p35 puncta pre-chemotherapy (Red arrows, Figure 3.6) while more cells 
were positive for p35 staining post-chemotherapy.  When all tumor samples were 
analyzed, there was a statistically significant increase in p35 staining (p = 0.026) across 
all 20 samples.  Interestingly, staining for p35 primarily appeared to be localized to the 
cellular surface of the plasma membrane in puncta, suggesting localization to an 
undetermined cellular structure (Figure 3.6).    
 
Discussion 
 Previous work from our laboratory has demonstrated the existence of therapy 
resistant, slow-cycling cancer cells.  Our efforts to identify differentially regulated 
transcripts between slow-cycling cells and rapidly proliferation cells using a qPCR array 
revealed consistent over-expression of the CDK5 activator p35, a relatively poorly 
studied protein in cancer.  The observation that p35 was over-expressed in not only 
tumors from an individual tissue of origin, but from tumors derived from multiple tissues, 
suggests that p35 activity may be a broadly used regulatory factor in maintaining slow-
cycling cancer populations (Table 3.1). 
 Consistent with the idea that p35 helps to maintain the slow-cycling phenotype of 
cancer cells, we observed a decline in S phase cells when p35 was over-expressed (Figure 
3.2C).  Interestingly, observations for the role of p35 on the cell cycle are not consistent 
throughout the literature.  The ability for p35/CDK5 to regulate E2F or p27 and suppress 
the cell cycle is inline with our observations of a decline of cells in S phase (14, 15).  In 
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contrast, other studies suggest a much different role, with p35 acting to push cells out of 
the G1 phase and into S phase and a G2/M arrest (131, 132).  It is likely that the 
localization and activity of p35/CDK5 may act as a gatekeeper into S and G2/M, with 
nuclear localization slowing the cell cycle and cytoplasmic localization and degradation 
allowing passage into S phase.  In neurons, Zhang et al. determined that CDK5 must be 
ubiquitinated and degraded in order for cells to progress into S phase (133).  This 
ubiquitinylation can be inhibited by p35 and suggests a mechanism within slow-cycling 
cancer cells that could explain the loss of cells actively progressing through S phase and 
their retention in the G1 phase of the cell cycle. 
 The broad range of proposed targets and functions of p35/CDK5 suggests a 
number of possibilities for the role of p35 over-expression in slow-cycling cancer cells.  
Curiously, we did not see evidence that p35/CDK5 may be acting on some of the more 
strongly associated targets like Tau, E-cadherin, and β-catenin (Figure 3.4 B and D).  In 
migrating neurons, p35 is demonstrated to free β-catenin from adhesion complexes, 
resulting in a re-localization away from the plasma membrane and potential endocytosis 
and degradation of E-cadherin (98, 124).  No change in localization pattern of either 
protein was observed during IF staining.  Several possibilities exist that may explain 
these observations including differences in CDK5 dependent and independent functions 
of p35 or differences in targets of full length p35 verses the cleaved form.  Western blot 
and immunoprecipitation experiments in cancer cells suggest that p35 is present primarily 
in the full-length form and that only a modest portion of this exists in complex with 
CDK5 (Figure 3.4A).  This data would suggest that the CDK5 independent functions of 
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p35 like E-cadherin down-regulation could be favored (98).  Nevertheless, we see little 
evidence for this type of activity.  Alternately, these observations may represent a context 
dependent functional shift in p35/CDK5 activity, unique to the tissue or cancer 
environment and availability of upstream and downstream signaling partners.  Future 
work will further clarify and address these questions.  
 Perhaps the most interesting and relevant finding is the association with p35 and 
cancer cell survival when treated with chemotherapy.  Expression of p35 increased cell 
survival after chemotherapy treatment, suggesting a protective role for p35 (Figure 3.3).  
Mechanistically, p35 protection may be due to interaction and stabilization with BCL2.  
Our striking IF data suggests a link between p35 expression and an increase in BCL2 
protein (Figure 3.4E, Row 4).  The clear puncta staining of BCL2 may indicate 
subcompartmental localization, likely to the mitochondria.  Curiously, p35 IHC staining 
of rectal cancer samples also resulted in cytoplasmic puncta staining and may suggest 
localization of p35 and subsequent stabilization of BCL2 at the mitochondria of rectal 
cancer cells (Figure 3.6).  Stabilization and activation of BCL2 by the p35/CDK5 
complex has been demonstrated through BCL2-p35 direct interaction and indirect 
interaction via the Erk pathway, suggesting that such protein interactions could be active 
in cancer cells (96, 97).  Slow-cycling tumor cells with increased p35 expression may 
elicit the opposite response, increasing resistance to apoptotic stimuli and ultimately 
protecting from cell death.  This data suggests that p35 may be an important factor in the 
BCL2 regulation in slow-cycling cancer cells.   
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 Initial profiling arrays between CFSE-high and CFSE-low cells identified p35 and 
BCL2 as the only two mRNA transcripts up-regulated throughout all the samples tested.  
While a connection between p35 and BCL2 is well established on the protein level, to 
date there is little evidence linking p35 activity to BCL2 transcription.  It is unclear if a 
link exists, or if this signature represents yet another layer of uncovered regulatory 
programming.    
 In conclusion, this work identifies the CDK5 regulator p35 as up-regulated in 
slow-cycling tumor cells.  We find that expression of p35 in HCT116 colon cells is linked 
to increased chemotherapy resistance and expression of the anti-apoptotic protein BCL2.  
Based on these findings, future work targeting p35 in combination with chemotherapy is 
worth exploring.  Ultimately, our work indicates future targeting of p35 via small 
molecule inhibition during and after chemotherapy may provide the means to target and 
eliminate therapy resistant cells, improving treatment efficacy and saving the lives of 
cancer patients. 
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Chapter IV: 
Slow-cycling Cancer Cells and Cancer Stem Cells 
 
Abstract 
 Cancer stem cell populations have been identified in epithelial tumors from the 
colon, breast, brain, prostate, and other cancer types.  Generally, these cell populations 
are identified using membrane markers such as CD133 and CD44; or functional assays 
such as cellular pump activity that have been associated with increased tumor-initiating 
capabilities.  We have determined that subsets of slow-cycling cells exhibited tumor-
reactivating abilities when live sorted and regrown as spheres or as tumors in mice.  
Despite these findings, slow-cycling CFSE label retaining cell populations are not 
enriched for expression of some of the most commonly used cancer stem cell markers.  
Our work suggests that slow-cycling cells, while not enriched for classical CSC markers, 
retain the ability to promote tumor formation and re-growth. 
 
Introduction 
 The existence of cancer stem cells (CSCs) was first demonstrated in leukemia by 
Bonnet and Dick in 1997 (56).  Since that discovery, CSC populations have been 
discovered in a multitude of other cancers from tissues including the colon (59-61), breast 
(52), brain (63), prostate (57), pancreas (58), and ovaries (62).  All cancer stem cell 
populations share three defining traits: first, they are long lived and self-renew 
throughout the existence of the tumor; second, they possess the potential to proliferate 
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indefinitely; and third, they can generate daughter cells with the ability to differentiate 
into any of the heterogeneous cell types found within the initial tumor.   Given these 
necessary traits, it is possible that CSCs are a result of the oncogenic transition of healthy 
adult stem cell populations.  Over time, mutations from inflammation, free radicals, and 
radiation/chemical exposure can accumulate to transform healthy adult stem cells into 
CSCs (48, 102).  
 Similar to the role that adult stem cells play in maintenance of tissue homeostasis, 
CSCs are thought to be important for tumor homeostasis and longevity.  Under the CSC 
model, as rapidly proliferating transit amplifying tumor cells drive tumor growth they 
eventually exhaust proliferative potential.  CSCs, with the ability to self-renew, undergo 
asymmetric division, produce new transit amplifying cells that continue to drive tumor 
expansion (54).  This importance in tumor homeostasis identifies CSCs as ideal 
therapeutic targets.  By better targeting CSCs or blocking CSC proliferation, the major 
driving force behind tumor growth and expansion could be eliminated.  Therefore, the 
identification and isolation of CSCs for further study is incredibly important in the fight 
against cancer. 
 One standard method of CSC identification involves isolating the cell population 
of interest from the tumor and looking for tumor initiating capability in immune-
compromised mice.  Traditionally, CSCs in these populations are identified using 
membrane markers that appear to be enriched for tumor initiating capability.  Bonnet and 
Dick discovered that the marker combination CD34+CD38 identified leukemia stem 
cells with the unique ability to initiate leukemia (56).  In some epithelial tumors like 
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those from the brain and colon, CD133+ cells are identified as enriched for the tumor 
initiating phenotype (60, 63).  In other epithelial tumors like the breast and pancreas, 
varying CD44 and CD24 combinations appear to enrich for CSC (52, 58).  In recent years 
however, markers for potential CSC populations have become increasingly numerous.  
For example, potential colon CSC markers have expanded to including CD44, EpCAM, 
ALDH, CD166, Lgr5, Bmi1, and others (134-136).  However in many cases, it is unclear 
how and if these populations overlap, obscuring the importance and significance of any 
one marker.  Additionally, the functional significance of many of these markers is 
unclear, with limited data suggesting these markers may have roles in self-renewal and 
proliferation, chemoresistance, migration, and engraftment potential (66).  For example, 
the frequently used CD44 marker is regulated by stem cell associated Wnt and Notch 
signaling (137-139).  Functionally, CD44 expression may support migration and 
chemotherapy resistance; both important characteristics for CSC associated populations.  
Additionally, CD133 appears to have connections with asymmetric cell division and 
multipotency, classic stem cell traits that promote tissue homeostasis and longevity (140, 
141).  Finally, ALDH is linked to cellular responses to stress and drug metabolism, 
suggesting roles in therapy resistance and survival (142, 143).  ALDH may serve to 
protect CSC populations from cell stress associated with rapidly expanding tumor 
environments or cytotoxic chemotherapeutic agents.  
 Unfortunately, none of these markers have been conclusively demonstrated to 
induce the CSC phenotype.  Like other CSC markers, CD133 colon tumor cells may be 
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enriched for the CSC phenotype but does not uniquely identify CSCs.  To date, no 
individual marker has been demonstrated to confer tumor-initiating capabilities. 
 Apart from membrane-associated markers, functional readouts like cellular pump 
analyses have also been reasonably successful at identifying CSC populations in tumors 
from the brain, breast, prostate, intestine, and ovaries (144-147).  By staining populations 
of cells with fluorescent dyes like Hoechst 33342, subsets of cells with increased cellular 
pump activity (such as ATP binding cassette transporters) pump out the dye and move 
away from the “main populations” towards the negative field on a flow cytometry plot, 
into a “side population”.  Functionally defining CSCs in this way may provide critical 
insight into how these cells respond to various therapeutic approaches.  For example, 
increased pump activity is likely to effect chemotherapy uptake and retention, thus 
decreasing DNA damage and the subsequent apoptosis caused by these drugs (148).  
Further study of these populations is therefore important in battling therapy resistance 
and tumor recurrence. 
 In this study, we characterize CFSE retaining, slow-cycling cancer cells in the 
context of a number of classic CSC markers using gene expression analysis.  
Additionally, we assay CFSE pulse/chased cells in relation to the side population because 
of the strong links to chemotherapy efflux.  Finally, we assay for the CSC phenotype by 
live sorting in vitro and in vivo CFSE-high and CFSE-low populations and directly 
assessing tumor initiating capabilities with limiting dilution assays.  While previous 
functional characterization of CFSE retaining cells and therapy resistance are relevant 
regardless of the marker status of the cells themselves, understanding how slow-cycling 
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cells fit into previously identified CSC populations is important in understanding their 
overall significance in the context of CSC biology.   
 
Results 
Slow-cycling cells are not enriched for common CSC markers 
 To place slow-cycling CFSE-retaining cells in context of other CSC markers, we 
performed quantitative PCR (qPCR) to detect variations in marker mRNA expression.  
CFSE pulse/chased samples from either in vitro spheres from the colon tumor line 
HCT116 or in vivo tumors from the tumor line HCT116, breast line MDA.MB.321, 
primary colon cancer samples 48116 and 2953T, or primary breast cancer sample 2597T 
were live sorted into CFSE-high and CFSE-low populations.  RNA and subsequent 
cDNA extracts from the resulting cells were used to conduct qPCR assays to analyze for 
differences in expression of potential CSC markers CD133, CD44, and the colon stem 
cell markers Lgr5 and Bmi1. Most tumors demonstrated increased expression of many 
markers in CFSE-high cells, however, we did not observe consistent differences of 
greater than two-fold for any of the makers analyzed (Table 4.1).   This data suggests that 
there is no clear pattern of surface marker expression linked with the slow-cycling 
phenotype. 
 To confirm these findings on the protein level, CFSE pulse/chased HCT116 in 
vitro spheres and in vivo tumors were digested to single cells and stained with antibodies 
against CD133, CD44, and ALDH.  It is worth noting that the standard assay for 
measuring ALDH activity is actually a fluorescent substrate-based metabolism assay, but  
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Table 4.1:  Slow-cycling cells are not enriched for CSC mRNA 
 HCT116 in vitro 
HCT116 
in vivo 2953T 48116 MDA231 2597T 
BMI1 1.52 1.16 0.82 1.03 2.39 1.59 
CD133 1.94 1.04 0.84 1.16 0.89 2.69 
CD44 2.25 1.22 0.91 1.21 2.05 1.74 
LGR5 3.16 1.33 0.91 1.10 1.91 3.07 
Values indicate fold CFSE-high expression relative to CFSE-low 
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the only commercially available dye for this assay conflicts with the CFSE label.  When 
CFSE-high and CFSE-low cells were separated by fluorescent analysis and the two 
populations were examined for marker intensity, we did not see any reproducible 
significant difference for either the in vitro (Figure 4.1A) or in vivo (Figure 4.1B) 
populations. This data confirms the initial array data and further suggests that there is no 
difference in expression of these CSC markers between slow-cycling cells and rapidly 
proliferating cells for the HCT116 colon line. 
 
Slow-cycling cells are not enriched in the side population 
 Given the chemotherapy resistance phenotype of slow-cycling cells observed in 
earlier studies (120), we next asked if slow-cycling cells demonstrate increased pump 
activity as part of the side population phenotype.  To identify the side population in these 
cells, we stained CFSE pulse/chased in vitro and in vivo populations with Hoechst 33342 
and analyzed for dye efflux by flow cytometry.  For cells found within the side 
population, cellular pumps remove dye from the cytoplasm, and cells become less 
fluorescent and move away from the labeled main population (Figure 4.2A).  To confirm 
that the cells identified as the side population are a result of cellular pump activity, 
control cells were treated with the pump inhibitor Fumitremorgin C (FTC), and the loss 
of the side population was observed (Figure 4.2A).  When the main population and side 
population were analyzed for CFSE levels, we observed that the side population was 
comprised of approximately one-half the percentage of CFSE-high cells relative to the 
main population.  These results were consistent for both in vitro and in vivo HCT116  
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Figure 4.1:  CSC markers do not enrich for slow-cycling cancer cells 
HCT116 CFSE pulse/chased spheres and tumors were stained for common CSC markers 
and evaluated by flow cytometry for marker expression.  (A) Representative expression 
profiles of CD133, CD44, and ALDH marker expression in CFSE-high (green) and 
CFSE-low (grey) cells in vitro.  No consistent significant difference was observed 
between CFSE-high (green) and CFSE-low (grey) cells.  (B) Representative expression 
profiles for in vivo CFSE-high and CFSE-low cells for the markers CD133 and CD44.  
No consistent significant difference was observed. 
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cells (Figure 4.2 B&C) as well as in vivo MDA.MB.231 cells (Figure 4.2D).  These data 
suggest that the side population does not enrich for slow-cycling cells and, in fact, may 
select against slow-cycling cells.  Furthermore, it suggests that the therapy resistant 
phenotype associated with slow-cycling cells in not due to increased pump activity. 
 
Slow-cycling cells are not enriched for tumor initiating capabilities 
 While markers and cellular pump activity may enrich for some populations with 
the CSC phenotype, the defining assay of a CSC is the ability to initiate tumor regrowth.  
To determine if in vitro slow-cycling sphere cells would enrich for the tumor initiating 
phenotype, we pulse/chased HCT116 spheres with CFSE and live sorted into CFSE-high 
and CFSE-low populations.  Equal numbers of CFSE-high and CFSE-low cells were 
replated at multiple dilutions in sphere media and incubated under standard conditions.  
After one week, spheres were counted and analyzed for size by longest dimension.  
CFSE-high and CFSE-low cells produced equal numbers of spheres at all dilutions 
(Figure 4.3A).  Interestingly, CFSE-high spheres were approximately half the size of 
CFSE-low cells (Figure 4.3B).  These data suggest that slow-cycling and rapidly 
proliferating tumor cells possess approximately equal tumor initiating potential, although 
unsurprisingly, slow-cycling, CFSE-high cells proceeded through the cell cycle fewer 
times over the given period. 
 To determine if slow-cycling cells were enriched for tumor forming ability in 
vivo, HCT116 tumors and 2597T primary breast tumors were pulse/chased with CFSE, 
live sorted into CFSE-high and CFSE-low groups, and then reinjected back into immune- 
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Figure 4.2:  Slow-cycling cells are not enriched in the side population 
(A) Representative flow cytometry plots of Hoechst stained samples.  Cells within the 
main population (blue) maintain dye while cells with increased cellular pump activity 
pump out dye and become the side population (red).  Population validation is achieved by 
culturing cells with the pump inhibitor Fumitremorgin C (FTC) and the disappearance of 
the side population.  For all samples (in vitro colon HCT116 (B), in vivo HCT116 (C) and 
in vivo breast MDA231 (D)), CFSE-high cells were not enriched for the side population.  
The percentage of CFSE-high cells in the side population was approximately half of the 
CFSE-high percentage in the main population. 
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compromised mice for dilution analysis.  All tumors for a specific dilution were isolated 
when the first tumor from the dilution reached 1000 mM3 or three months after injection.  
HCT116 CFSE-low cells demonstrated the ability to consistently produce tumors with as 
few as 500 cells (3/3 mice) (Table 4.2).  In contrast, HCT116 CFSE-high cells were only 
able to consistently produce tumors when at least 5,000 cells were injected (3/3 mice), 
and demonstrated limited ability to initiate tumor growth at 1,000 cells per injections (1/3 
mice).  When the primary breast tumor 2597T was evaluated for tumor-initiating 
capability, CFSE-high cells produced a single tumor with 50,000 injected cells, but 
CFSE-low cells were unable to initiate tumor growth even at 100,000 cell injections 
(Table 4.2).  These data suggest that slow-cycling cells demonstrate tumor initiating 
ability in at least a subset of cells, but that this initiating ability may not be enriched over 
that of bulk tumor cells. 
 
Discussion 
 The relationship between cancer stem cells markers and slow-cycling cells is 
likely complex and multivariable.  CSC surface markers are expressed in slow-cycling 
cells, but the available evidence from the literature and our data collected in this work 
does not suggest an exclusive relationship between the two populations (149).  It is 
possible then, that cells moving in and out of the proliferative state may oscillate 
expression of CSC markers depending on the functional role of the specific marker.  For 
example, the role of CD133 in asymmetric division may suggest increased expression in 
preparation for cell division, while returning to a baseline expression level during gap and  
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Figure 4.3:  In vitro slow-cycling are sphere forming  
Live sorted CFSE-high and CFSE-low cells were replated in sphere media at multiple 
dilutions.  (A) After one week, CFSE-high (green) and CFSE-low (grey) cell populations 
were able to form equal numbers of spheres at all dilutions assessed.  (B) CFSE-high 
sphere diameters (green box) were approximately half the size of CFSE-low sphere 
diameters (grey box) (81.71 units to 45.43 units, p < 0.001). 
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Table 4.2: In vivo limiting dilution analysis 
HCT116 
Dilution CFSE-high CFSE-low 
5,000 3/3 3/3 
1,000 1/3 3/3 
500 0/3 3/3 
100 0/3 0/3 
   
2597T Breast 
Dilution CFSE-high CFSE-low 
100,000 - 0/2 
50,000 1/2 0/2 
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synthesis phases.  In this way, tumor initiating slow-cycling cells would move into the 
CD133 positive population just before division in preparation for asymmetric division 
and return to the CD133 negative population during the rest of the cell cycle and the cell 
cycle stall.  With only a fraction of slow-cycling cells positive for CD133 at any one 
time, they may not enrich for marker expression at detectable levels. 
 The HCT116 cells primarily utilized in these studies may not conform to a stem 
cell model hierarchy associated with any present CSC marker, but may maintain 
themselves via a stochastic model with no functionally meaningful marker variations 
(150).  Under such a model, slow-cycling cells may then be a dynamic population in 
which cells transition in and out of the slow-cycling state depending on environmental 
and cellular cues and independent of CSC marker expression.  The HCT116 line 
highlights the independence of slow-cycling cells from the CSC marker model and 
suggests that the slow-cycling phenotype may not be as closely linked with the CSC as 
originally hypothesized.    
 In contrast, other cell lines do appear to be hierarchically arranged, with stem-like 
cell populations identified by specific markers.  It may then be possible that CSC marker 
expression within these cells is more functionally relevant. Repeating the analysis from 
this study in some of these cell lines may be more apt to address how slow-cycling cells 
definitively relate to CSC markers (68, 151). 
 Identifying slow-cycling cells as enriched within the side population would 
associate slow-cycling cells with other CSC populations and suggested a potential 
mechanism to explain previous data demonstrating increased therapy resistance in slow-
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cycling cancer cells.  Unfortunately, slow-cycling cells were less frequently found in the 
side population in relation to the main population (Figure 4.2).  While this data indicates 
that slow-cycling cells do not coincide with previously described CSC populations, it also 
suggests that cellular pump activity is not contributing to the increased therapy resistance 
phenotype observed in this cell population.   
 Combining tumor-initiating potential from both the in vitro and in vivo data does 
not present a clear picture of slow-cycling cell tumor-initiating potential.  In vitro 
evidence would suggest that both CFSE-high and CFSE-low cells are tumor forming with 
approximately equal tumor-initiating potential (Figure 4.3).  On the other hand, in vivo 
evidence suggests two different answers, with slow-cycling cells both enriching for 
tumor-initiating cells in the primary breast sample and selecting against tumor-initiating 
cells in the HCT116 line (Table 4.2).  Results from other groups indicate similar patterns 
to that seen with the 2597T primary breast tumor sample, mainly that slow-cycling cell 
populations were enriched for the tumor-initiating phenotype over more rapidly 
proliferating cells (40, 62, 68).  Curiously, our in vitro data would suggest that slow-
cycling HCT116 cells are highly tumor-initiating, leading us only to speculate why in 
vivo cells demonstrated less tumor-initiating potential.  While not clearly understood, we 
suspect that relatively harsh dissociation techniques required to generate single cell 
suspensions from tumors is likely contributing to the poor tumor-initiating frequency in 
vivo.  In comparison to sphere-forming assays that only require rapid and light 
trypsizination, tumors are first excised from mice then digested for hours in protease, 
before being heavily mechanically and enzymatically dissociated.  These factors are 
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stressful to cells and likely contribute to a distressed state that may favor poor grafting 
and proliferation.  Isolation of relatively few numbers of slow-cycling cells during live 
sorts may further affect cell health and grafting ability.  Future experiments will need to 
be aimed at addressing this question in more depth.  
 In conclusion, our data does not suggest enrichment of slow-cycling cancer cells 
by any of the popular CSC markers.  Additionally, slow-cycling cancer cells do not 
demonstrate increased cellular pump activity and enrichment within the side population.  
Regardless of the CSC marker status of CFSE retaining cells, our data demonstrates that 
at least a sub-population of slow-cycling cells are able to lead to the formation and 
potential regrowth of tumors.   
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Chapter V: 
Discussion and Conclusions 
 
 The existence of slow-cycling adult stem cell populations is important for long-
term maintenance of adult tissues.  Adult stem cell populations, like those in the breast 
and colon, have been demonstrated as the cells of origin for many CSC populations that 
drive tumor growth.  As a result of this oncogenic transition, adult stem cell 
characteristics, like slow-cycling and inherent therapy resistance, are likely retained in 
CSC populations.  Regulation of the slow-cycling phenotype is a complex process that 
relies on signaling from various stem cell-associated pathways as well as precise 
interaction between CDKs and their inhibitors, all of which may provide novel targets for 
cancer therapeutics. 
 This work utilizes a novel application for the cell proliferation marker CFSE to 
identify, isolate, and characterize live slow-cycling cancer cells.  We demonstrate that 
slow-cycling cancer cell are present in both cultured cell lines and primary tumors.  
Additionally, slow-cycling tumor cells were found to have a multi-fold resistance to 
traditional forms of chemotherapy when compared to bulk tumor cells.  Regulation of this 
resistance phenotype may be due to increased expression of the CDK5 activator p35 and 
the ability for this protein to interact with anti-apoptotic BCL2.  We demonstrate that 
changes in expression of p35 are associated with similar changes in cell survival in 
response to chemotherapy treatment.  Furthermore, increased expression of p35 was 
demonstrated to increase BCL2 staining and suggests stabilization of BCL2 by p35.  
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Immunohistochemical staining of pre- and post-chemotherapy rectal tumors suggest that 
expression of p35 may have clinical relevance in helping cells survive chemotherapy and 
potentially lead to recurrence.  Finally, we observed that slow-cycling tumor cells did not 
enrich for commonly used CSC markers, but did demonstrate limited ability to initiate 
tumor growth independent. 
 Combined, our work demonstrates the existence of a slow-cycling cancer cell 
population with limited tumor initiating capabilities and increased resistance to traditional 
forms of chemotherapy.  Importantly, this work identifies a population of cells with the 
potential to drive tumor recurrence in patients and beings to explore future ways to better 
target these cells.  
 
CFSE Label Retaining Cells 
 The use of the fluorescent label CFSE is central to the identification of slow-
cycling cancer cells in this body of work.  At the onset of this project, the use of CFSE to 
identify slow-cycling cancer cells was a novel application that offered important 
differences in previously attempted pulse chase methods:  first, CFSE is fluorescent in 
live cells; second, CFSE binds to internal proteins within the cell and is not subject to 
asymmetric segregation; and third, CFSE is detectable for up to ten passages after initial 
staining.  Early identification of slow-cycling cells often utilized nucleic acid analogues 
like BrdU.  Identification of these compounds requires the utilization of both antibodies 
and denaturation of DNA, which kills the cells.  Any form of tumor-initiating assay or 
characterization requiring live cells is not possible using these methods.  In contrast, the 
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fluorescent nature of CFSE provides a means of sorting live cells, allowing for assay and 
characterization without their destruction. 
 Interestingly, recent findings suggest that the use of nucleic acid analogues may 
not always identify cells based on their slow-cycling characteristics.  In fact, these labels 
often identify continuously proliferating cells that asymmetrically segregate DNA, to 
preserve the original (replication error free) “template strand” (152, 153).  The use of 
DNA analogues in such a cell population would not assay for the slow-cycling phenotype 
as intended.  In comparison, CFSE would still be expected to identify a more slow-
cycling cell population regardless of the “template strand” retention phenotype.  In light 
of these discoveries, it may be important to revisit previously identified nucleotide 
analogue label-retaining cell populations and re-evaluate the mechanisms of label 
retention and implications. 
 More recent attempts to study slow-cycling cells have utilized lipophilic 
fluorescent dyes like the PKH dyes (PKH2, PKH26, PKH67).  Membrane fluorescent 
labels solve many of the problems associated with nucleotide analogues, specifically the 
ability to track label in live cells.  Notably, CFSE offers advantages over these dyes in the 
method of labeling and processing options.  In contrast to the covalent labeling of CFSE 
to amine groups, PKH dyes are non-covalently bonded (154).  These non-covalent bonds 
are sensitive to solvents and fixatives that may be required in further cell staining or 
molecular biology techniques.  Additionally, these dyes label less homogeneously, 
potential masking slow-cycling cells. 
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Slow-cycling Cells and Cancer Stem Cells 
 The association between slow-cycling cancer cells and cancer stem cell 
populations has been demonstrated by multiple groups in various tumor types (40, 68, 
72).  Through limiting dilution analysis, our work demonstrated the ability of in vitro 
slow-cycling cells to efficiently form spheres at rates equal to more rapidly proliferating 
cells.  In contrast, in vivo slow-cycling cells were able to initiate tumor growth, but 
required much higher quantities of cells relative to more rapidly proliferating cells.  
These findings suggest that unlike a CSC population, slow-cycling cells have equal or 
diminished tumor initiating abilities compared to bulk tumor cells.  Further validating 
these findings, our slow-cycling cells were not enriched for three of the most commonly 
used markers for identifying CSC populations. 
 We conclude that slow-cycling cells are not more stem-like in nature than 
unsorted or bulk tumor cells.  Our data demonstrates that a sub-population of slow-
cycling cells is tumor propagating, and suggest that this ability is dependent on cell 
environment and context.  Interestingly, these data imply that the slow-cycling phenotype 
may not be related to retention of the slow-cycling characteristic from adult stem cells to 
transformed cancer stem cells during oncogenic transition.  Instead, this phenotype may 
be a naturally occurring process regulated by cell-cell communications and 
environmental cues with yet undefined purposes. Alternatively, the generation of slow-
cycling cells may be a secondary effect of other tumor processes such as moving in and 
out of a proliferative state due to EMT as described by Dembinski and Krauss (72).  
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Whether the slow-cycling cell phenotype remains important for long-term tumor 
maintenance and homeostasis as observed in adult tissues is unclear.  
 Importantly, the inability to define slow-cycling cells as cancer stem cells is 
inconsequential to the major biological findings throughout this body of work.  We 
demonstrate a slow-cycling population of cells with increased chemotherapy resistance 
and the ability to progress through the cell cycle following the cessation of treatment.  
These traits identify slow-cycling cells as potential drivers of tumor recurrence regardless 
of marker status and the ability to enrich for tumor initiating cells.   
 
Profiling Slow-cycling Cancer Cells 
 The qPCR array used to assay transcript differences between CFSE-high and 
CFSE-low cell populations was focused on identifying potential changes in stem cell 
associated pathway activities and families of proteins that may regulate slow-cycling and 
survival.  Primarily of interest, this array looked at many of the CDKs including CDK 
2,4,and 6, as well as CKIs including CDKN1A (p21), CDKN1B (p27), CDKN2A (p16).  
Additionally, the array analyzed other cell cycle and quiescence related factors like 
PCNA, NFAT1c, and Rb.  Surprisingly, even factors with strong support in published 
literature for slow-cycling cell regulation, like p21, did not demonstrate consistently 
significant differences across all samples, suggesting that different mechanisms of slow-
cycling cell regulation may be at work.  It is possible that patterns of regulation may exist 
within specific cell lines or across tumor types.  Both in vitro and in vivo HCT116 colon 
slow-cycling cells had increases in p21 expression relative to bulk cells, while both breast 
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tumor derived slow-cycling cells (MDA231 and 2597T) had increases in p16 expression 
relative to bulk cells.  In contrast to these results, the two primary colon tumors did not 
demonstrate meaningful differences in any CKI or cell cycle related CDKs. These data 
suggest that regulation of the slow-cycling phenotype may be tumor dependent, with 
different mechanisms converging to produce slow-cycling cells.  These observations 
imply an important role for slow-cycling cells in cancer homoeostasis, while presenting 
great difficulty in identifying targets and creating applicable therapeutics to eliminate 
slow-cycling cells.  Alternate regulation of slow-cycling cells between tumor types may 
require identification and implementation of unique drugs for each mechanism for slow-
cycling regulation. 
 Most importantly, the consistent over-expression of p35 (CDK5R1) across all 
samples suggests that a novel, poorly understood mechanism of cell cycle control may be 
contributing to the slow-cycling cell phenotype.  A single mechanism is further supported 
by the consistent up-regulation of BCL2 and its established relationship with p35.  
Conserved p35/CDK5 and BCL2 activity across tumors from multiple subtypes and 
organs suggests an essential underlying function of this complex.  Clinically, a single 
underlying mechanism for slow-cycling cells may make possible the use of a single 
therapeutic agent aimed at p35/CDK5 activity that would be applicable across a broad 
range of tumors. 
 
Knockdown of p35 in Slow-cycling Cancer Cells 
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 Throughout this study, we consistently observed little change in cell cycle profile 
or effect on p35 target genes in cells with down-regulated p35 signaling.  Two likely 
explanations exist to explain these findings:  first, that because the use of shp35 vectors 
resulted in ~50% loss of mRNA transcripts, the overall p35 protein may still be 
biologically significant or unchanged, or second, that loss of p35 only affected the small 
population of slow-cycling cells and that the resulting global changes were undetectable.  
Both of these hypotheses could explain why western blots failed to detect changes in p35 
targets when p35 is down-regulated.  If, for example, p35 can lead to the endocytosis and 
degradation of E-cadherin in cancer cells (98), under the first hypothesis the remaining 
p35 protein is still sufficient to reduce E-cadherin resulting in equal E-cadherin 
expression to shGFP controls.  Under the second hypothesis, p35 would only be down-
regulated in the 2-4% of slow-cycling cells and with the relative insensitivity of western 
blotting techniques, the resulting minor E-cadherin increase would not be distinguishable. 
 In support of the second hypothesis, we did observe a difference between shp35 
clones and the shGFP control when cultures were treated with chemotherapy.  By killing 
off a large percentage of our cells with chemotherapy we enrich for the slow-cycling 
(presumably p35 over-expressing) cells.  Loss of p35 resulted in reduced total cell 
number.  If p35 mRNA knockdown was not significantly changing p35 protein levels, we 
would not expect to see a difference in survival between shp35 clones and shGFP 
controls.  Therefore, these data support a hypothesis in which loss of p35 is only affecting 
a relatively small percentage of cells.  By eliminating up to 90% of total cells with 
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chemotherapy, the further loss of cells reliant on p35 for survival is magnified and would 
explain the increased death observed in shp35 clones. 
 
p35 and the Slow-cycling Cell Phenotype 
 Key to the observations and discoveries in this work is the role of p35 in 
regulation and control of the cell cycle in slow-cycling cells.  Interestingly, we observed a 
major disparity in cell cycle profiles between CFSE-labeled slow-cycling cells and those 
cells in which p35 is artificially over-expressed.  CFSE-labeled slow-cycling cells 
demonstrated an increase in G2/M phase cells, while CMV-p35 cells demonstrated a 
diminished number of cells in S phase in favor of the G1 state.  A possible explanation 
for these findings may be due to increased stress levels resulting from artificial over-
expression of a protein.  This stress may disrupt the cell cycle and provide distorted 
results.   
 Alternately, it is likely that simple over-expression of p35 is not a complete 
replication of the CFSE-labeled slow-cycling cell phenotype.  Other factors beyond p35 
over-expression are likely differentially regulated between CFSE-high and CFSE-low 
cell populations, which may further contribute to cell cycle regulation and the disparities 
observed in cell cycle profiles.  These differences are also likely to involve changes in 
target availability, resulting in differential p35/CDK5 downstream signaling between 
slow-cycling cells and p35 over-expressing cells.   Complete transcript profiling of 
CFSE-high and CFSE-low cell populations would identify alternately regulated 
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transcripts between the two cell populations beyond those evaluated here, and help to 
create a more complete picture for slow-cycling cell regulation. 
 Additionally, artificial expression of p35 beyond that observed at endogenous 
levels may lead to over-saturation of CDK5 binding.  Without CDK5 as a binding 
partner, p35 activity may favor an increase in CDK5-independent activity.  No studies to 
date link unbound p35 independent activity directly with regulation of cell cycle control.  
However, independent functions of p35 do include regulation of E-cadherin and potential 
release of β-catenin into the nucleus (98).  We found E-cadherin and β-catenin 
localization patterns to be unchanged in p35 expressing cells during our studies, 
suggesting p35 may not be functioning independently of CDK5 and that other factors 
may be contributing to differences in cell cycle profiles.  Experiments that over-express 
CDK5 both independently and with p35 would further elucidate the specific role of p35 
in cell cycle regulation. 
 Finally, cell cycle profile differences between slow-cycling cells and p35 over-
expressing cells may be a characteristic of localization of p35/CDK5 and the resulting 
effect on the cell cycle.  Cytoplasmic p35/CDK5 may lead to ubiquitylation and 
degradation, creating a permissive environment for premature entry into S phase, where 
cells are proposed to stall due to incomplete signaling requirements for completion of 
mitosis (131, 133). In contrast, the localization of p35/CDK5 into the nucleus has been 
associated with interactions with both p27 and Rb, contributing to inhibition of the cell 
cycle (2, 15).  Over-expressed p35 protein was primarily located in the cytoplasm, but 
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nuclear protein was present.  Even the low nuclear staining observed must be enough to 
stall the p35 over-expressing cells in G1 as determined by cell cycle profiles.  
 From these findings, we conclude that p35 regulates the cell cycle by working 
with CDK5 to block entry into S phase and stall cells within the G1 phase of the cell 
cycle.  This block is potentially through p35/CDK5 interactions with p27 and E2F, 
although future experiments will need to validate this relationship experimentally.  While 
this body of work does not explore G0 associated signaling, cell cycle analysis and label 
dilution experiments suggest that CFSE-high cells are actively cycling.  Therefore, it is 
likely that these cells are not in a more permanent G0 stalled state.  Furthermore, there is 
little background or experimental evidence to suggest that p35 over-expression in slow-
cycling cells is directly leading to the G2/M stall observed in CFSE label retaining cells.  
We propose that this G2/M stall is a side effect of increased apoptosis resistance in this 
cell population.  CFSE LRCs within the G2/M state may be reacting to cell stress or 
DNA damage by stalling for repairs.  While bulk cells may undergo apoptosis during this 
stall, increased survival proteins like BCL2 may promote repair over apoptosis and lead 
to a buildup of cells in the G2/M phase of the cell cycle. 
 
p35 and Implications for Metastasis 
 In the developing brain and postmitotic neurons, p35 plays a key role in 
regulation of cytoskeletal structures during cell migration (11, 100).  Over-expression of 
p35 demonstrated lattice-like staining patterns consistent with association with 
cytoskeletal structures.  Interestingly, p35 did not appear to alter PHF-1 motif 
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phosphorylation levels of the microtubule stabilizer Tau, suggesting Tau may not be a 
target of p35 in slow-cycling cancer cells.  Alternatively, the localization of p35 may 
reflect regulatory activity on other cytoskeletal targets.  The functional implications for 
these findings are unclear, but p35 expression may suggest an increased ability for 
migration within slow-cycling cancer cells.  If validated, these findings would have vast 
implications for slow-cycling cancer cells as strong candidates for drivers of metastasis.  
Increased migratory abilities of slow-cycling cells would allow for movement through the 
matrix and into the blood.  At the same time, increased anti-apoptotic abilities in slow-
cycling cells via BCL2 would promote survival within the foreign environments of both 
the blood and metastatic tissues.  Finally, slow-cycling cell tumor-initiating abilities 
would promote establishment and metastatic outgrowth.  Future research should look at 
induction of migration and the effects on metastasis in p35-expressing cells.   
 
Targeting CDKs and p35/CDK5 in Therapeutics 
 Pathways linked to expression of CDKs are often dysregulated in cancer, making 
them natural targets for therapeutics.  Mutations of CKIs, CDKs, cyclins, and Rb all 
contribute to aberrant CDK activation and tumor cell proliferation (155).  Targeting 
CDKs with the goal of stopping cell growth and inducing apoptosis is an appealing 
option when faced with the rapid expansion and mutational diversity characteristic of 
cancer progression.  Targeting CDKs in solid tumors has generated mixed results.  Small 
molecules, such as Flavopiridol, that broadly target CDK activities do not appear to be 
very effective at tolerated concentrations on a broad scale (156, 157).  However, low 
 120 
percentages of clinically measurable partial and objective responses have been observed 
with Flavopiridol, suggesting that selecting the right tumors may be important when 
using CDK inhibitory drugs.  Paradoxically, enhanced toxicity of DNA damaging agents 
like Oxaliplatin and 5-Fluorouracil are observed when used in combination with CDK 
cell cycle inhibitors (158, 159).  The reasons why targeting proliferation activity 
increases activation of cell cycle dependent drugs is unclear, but may suggest that more 
than simple cell cycle inhibition is achieved through broad inhibition of CDKs.   
 Interestingly, drugs more specifically targeting p35/CDK5, like roscovitine and 
SCH727965, have had few clinically relevant responses in solid tumor xenografts and in 
patients (160, 161).  Primarily, these studies measure response of tumors in the form of 
changes in tumor size and total cell response, observing little, if any, tumor regression.  
In contrast, our work identifies a subset of p35 regulated slow-cycling cancer cells that 
become enriched following treatment with traditional chemotherapies.  Manipulations of 
p35 further increased or decreased survival relative to the amount of p35 expressed.  
These data indicate that the p35 slow-cycling phenotype contributes to chemotherapy 
survival in only a subset of cells.  
 Importantly, inhibition of p35/CDK5 in combination therapy may allow for more 
direct targeting of therapy resistant cancer cells, limiting damage to normal adult tissues.  
Unlike other CDKs, Rb, and other cell cycle related drug targets that are critical in adult 
tissues, p35 activity may be limited to tumor populations.  The use of more specific 
p35/CDK5 inhibitors, like roscovitine and SCH727965, is well tolerated in adult tumor 
patients without adverse impacts, suggesting that long term loss may have limited side 
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effects on adult healthy tissues (161, 162).  Unfortunately, use of p35/CDK5 inhibitors in 
pediatric cancers may not be an option.  Pre-natal p35 knockout mice fail to develop 
proper cortical layering, suggesting that p35 inhibition may hinder proper neural 
development in young children (123).  
  Our data would suggest that drugs like roscovitine and SCH727965 may have the 
greatest efficacy on the p35 expressing, slow-cycling subset of cells.  As a single agent, it 
therefore is not surprising that a profound response in tumors is not observed if only a 
small percentage of p35 expressing cells are being targeted.  Even in combination with 
chemotherapeutics, a measurable difference in tumor size may not be expected.  A more 
appropriate measurement of response to these drugs may be changes in recurrence rates 
and time to recurrence.  Our data suggest that p35/CDK5 plays an important role in 
slowing the cell cycle and increasing anti-apoptotic BCL2 family members.  These 
regulations mitigate DNA damage and mitochondrial-associated apoptotic signaling 
induced by chemotherapeutics reliant on cycling cells. The use of p35/CDK5 inhibitors 
before or in combination with chemotherapy will block the anti-proliferative effects of 
p35/CDK5, pushing slow-cycling cells into the cell cycle and making them more 
susceptible to DNA damage.  At the same time, less active p35/CDK5 will decrease 
stabilized BCL2, reducing anti-apoptotic signaling and driving cell death.  With the 
elimination of slow-cycling therapy resistant cells, tumor cell survival may be decreased 
and recurrences should decline. 
 
Conclusions and Model 
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 Based on the findings of this work, we propose a model in which epithelial 
tumors like those of the breast and colon have an inherent p35/CDK5 regulated slow-
cycling cell population that exists to support and replenish rapidly proliferating cells 
(Figure 5.1). These slow-cycling cell populations further utilize p35 to promote cell 
survival through stabilization of proteins like BCL2.  In response to traditional 
chemotherapeutic agents, the slow-cycling nature of these cells reduces their overall 
chemosensitivity; while at the same time, anti-apoptotic BCL2 activity would promote 
better resistance to death signaling.  Finally, following the cessation of treatment, slow-
cycling resistant cells are able to re-enter the cell cycle and reactivate tumor growth and 
expansion.  This tumor growth leads to patient recurrences and all too often death. 
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Figure 5.1:  p35 regulation of slow-cycling cells in cancer 
Within tumors, sub populations of slow-cycling stem-like cancer cells increase 
expression of the CDK5 activator p35 to regulate cell cycle and promote tumor 
homeostasis.  Additionally, p35/CDK5 directly or through Erb/Akt/PI3K signaling 
stabilizes the anti-apoptotic protein BCL2.  In response to traditional forms of 
chemotherapy that induce DNA damage, stabilized BCL2 works to inhibit pro-
apoptotic BH3 family members, preventing the activation of caspases and promoting 
increased cell survival over bulk tumor cells.  Following chemotherapy cessation, the 
stem-like abilities of slow-cycling cancer cells drives tumor reactivation and 
recurrence.  
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Appendix I 
BH3 Profiling in Slow-cycling Cancer Cells 
 
 Treatment of tumors with traditional forms of chemotherapy induces cell stress 
through DNA damage.  This DNA damage ultimately signals for the up-regulation of 
pro-apoptotic BH3-BCL2 family members that lead to the formation of mitochondrial 
membrane pores and the release of cytochrome C to drive cell death (86, 88).  Anti-
apoptotic BCL2 family members, like BCL2, sequester pro-apoptotic BCL2 BH3 family 
members and inhibit pore formation, promoting survival.  Through regulation and 
interaction of pro-apoptotic and anti-apoptotic BCL2 family members, cells can become 
more or less primed to undergo apoptosis.  Our findings suggest that p35 may function to 
stabilize BCL2 and increase overall protein, inhibiting formation of mitochondrial 
membrane pores, and priming slow-cycling cancer cells to be less susceptible to death 
signaling. 
 To evaluate the role of p35 and BH3-family interaction, we conducted pilot work 
with the Letai Lab at Dana-Farber to profile slow-cycling cancer cell apoptotic priming in 
response to BCL2-BH3 family members (87).  In vitro spheres pulse/chased with CFSE 
for one week or in vivo labeled tumors pulse/chased with CFSE for two weeks were 
digested to single cells and cultured with peptides that mimic BCL2-BH3 family 
members.  These BCL2-BH3 peptide mimics are designed to promote apoptotic signaling 
and induce mitochondrial membrane depolarization.  Treated cultures were then stained 
with a compound (JC-1) that is fluorescent green in healthy mitochondrial matrices, but 
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changes to fluorescent red when mitochondrial membranes are permeabilized. The JC-1 
compound allows for the identification of mitochondria that have undergone membrane 
depolarization via flow cytometry.   
 When compared to CFSE-low cell populations, CFSE-high in vitro cells 
demonstrated decreased membrane depolarization in response to several of the BH3 
peptides, suggesting less apoptotic priming and more resistance to certain forms of death 
stimuli (Appendix I Figure 1A, n=2).  In contrast to these results, in vivo populations did 
not demonstrate detectable difference in mitochondrial depolarization between CFSE-
high and CFSE-low populations (Appendix I Figure 1B, n=2).  These early data suggest a 
potential for increased resistance to apoptotic signaling in CFSE-high cells that may be 
context dependent and further regulated by the presence of in vivo signaling not 
replicated in vitro.  It is likely that regulation of apoptotic signaling in vivo is more 
complex and less responsive to any single input than any current in vitro model. 
In order to understand the role that p35 may have on priming cells to apoptotic 
stimuli, we repeated the BCL2-BH3 profiling on HCT116 cells expressing shp35 
constructs (Appendix I Figure 1C, n=1).  In comparison to shGFP controls, both 
constructs demonstrated increased depolarization of the mitochondrial membrane for 
almost all peptides explored. These preliminary data indicate that loss of p35 expression 
increases cell susceptibility to apoptotic signaling. 
 Although these findings are preliminary, the in vitro studies complement the 
chemotherapy treatment assays and suggest that slow-cycling cells are resistant to 
apoptotic death signaling.  Furthermore, these studies suggest a mechanism  
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Appendix I Figure 1: BH3 Profiling of slow-cycling cancer cells 
HCT116 CFSE pulse/chased spheres, tumors, and shp35 clones were profiled for BH3 
family peptide priming and mitochondrial membrane depolarization by JC-1 staining 
and flow cytometry.  (A) In vitro CFSE BH3 profiling of CFSE-high (green) and CFSE-
low cells (grey).  CFSE-high cells demonstrated less mitochondria depolarization to 
BH3 peptide mimics for BIM, BAD, PUMA, and HRK (n=2) but did not reach 
statistical significance. (B) In vivo CFSE BH3 profiling of CFSE-high (green) and 
CFSE-low cells (grey).  No significant difference was observed between CFSE-high and 
CFSE-low cells in vivo (n=2).  (C) In vitro CFSE BH3 profiling for HCT116 shGFP 
(grey), shp35-G6(blue), and shp35-G8(purple) clones. Loss of p35 is associated with 
increased mitochondria depolarization for the majority of BH3 peptides assessed (n=1). 
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through which p35 promotes the BCL2 ability to block pro-apoptotic BCL2 BH3 family 
pore formation and apoptosis.  It would be interesting to expand these assays to include 
HCT116 cells over-expressing p35.  If this proposed mechanism is valid, p35 over-
expression should further limit mitochondrial membrane depolarization and promote cell 
survival.  Future repetition and expansion of these assays to include inhibitors for both 
p35 and BCL2 will help to better define interactions between these two proteins.  
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Appendix II 
Complete qPCR Array 
 
HCT116 
In Vitro 
(n=2) 
HCT116 
In Vivo 
(n=3) 
2953T    
In Vivo 
(n=1) 
48116    
In Vivo 
(n=1) 
MDA231 
In Vivo 
(n=3) 
2597T    
In Vivo 
(n=1) 
ABL1 2.51 3.47 1.22 0.73 1.75 3.13 
ADAR 2.65 0.38 0.64 0.85 0.95 1.74 
ANAPC2 2.90 1.58 1.05 1.64 1.23 1.28 
ANAPC4 1.21 2.14 0.79 0.74 1.63 1.06 
APC 1.98 1.51 0.84 0.60 2.78 1.77 
ASCL2 3.03 3.57 0.78 0.92 1.08 1.68 
ATM 2.54 0.98 0.74 1.39 0.73 2.80 
ATR 2.10 1.76 0.93 0.77 1.19 1.00 
AXIN1 3.43 1.89 1.03 0.88 1.22 1.84 
BCCIP 1.16 0.82 0.74 0.82 1.58 1.01 
BCL2 3.05 3.67 1.89 2.38 5.74 3.43 
BMI1 1.52 1.16 0.82 1.03 2.39 1.59 
BRCA1 1.72 1.18 0.65 0.64 1.09 1.25 
BRCA2 1.56 1.12 0.74 0.59 1.85 2.23 
BTRC 2.60 2.53 0.74 0.62 1.52 1.93 
CCNA2 1.33 1.65 1.17 2.08 3.79 0.90 
CCNB1 0.88 1.50 0.98 1.56 2.18 0.83 
CCNB2 0.92 1.32 0.80 1.36 2.13 1.07 
CCNC 1.04 1.28 0.89 0.92 1.80 0.99 
CCND1 3.76 1.81 1.17 0.74 0.96 1.82 
CCND2 3.03 3.26 0.79 1.18 1.77 2.26 
CCNE1 2.22 0.48 0.92 0.66 1.35 0.96 
CCNF 2.67 0.77 0.71 0.76 50.87 1.58 
CCNG2 2.89 0.93 0.79 0.60 4.55 2.80 
CCNH 1.38 4.02 1.06 0.94 2.15 2.09 
CCNT1 2.23 0.76 0.72 0.66 1.25 1.65 
CCNT2 2.80 0.89 1.21 2.01 2.04 2.67 
CD133 1.94 1.04 0.84 1.16 0.89 2.69 
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CD44 2.50 1.22 0.91 1.21 2.05 1.74 
CDC16 1.86 0.84 0.92 1.59 1.26 1.82 
CDC2 1.59 2.98 1.23 1.38 2.02 1.36 
CDC20 1.11 0.72 0.91 1.06 0.93 0.92 
CDC34 3.05 1.42 1.18 2.88 5.20 1.87 
CDC42 1.58 1.67 1.47 4.30 2.63 1.19 
CDK2 1.48 0.45 1.17 0.77 1.50 2.01 
CDK4 1.17 1.50 0.86 1.21 2.26 1.38 
CDK5R1 2.63 2.39 7.09 3.81 1.79 6.57 
CDK6 2.61 3.12 0.92 1.05 3.55 1.71 
CDK7 1.71 1.11 0.96 0.75 1.16 1.42 
CDK8 1.75 0.81 0.81 0.92 3.27 1.33 
CDKN1A 2.65 2.45 1.00 0.77 1.49 2.56 
CDKN1B 2.52 1.18 0.97 0.79 2.37 1.36 
CDKN2A 1.07 0.96 0.95 0.83 4.93 5.08 
CDKN2D 1.66 0.63 0.82 0.94 1.01 1.14 
CDKN3 1.11 0.57 1.26 1.29 1.24 1.40 
CHEK1 1.70 2.27 0.83 0.66 2.42 1.39 
CHEK2 2.22 0.90 1.04 0.89 1.05 2.60 
CKS1B 1.03 2.05 1.07 0.96 1.89 1.19 
CUL1 1.12 0.68 0.72 0.82 1.13 1.15 
CUL2 1.27 2.14 0.91 0.96 1.31 1.30 
CUL3 2.40 1.06 0.91 0.81 1.80 2.05 
DDX11 3.62 1.28 1.25 1.39 3.83 2.47 
DIRAS3 1.20 1.40 0.51 1.09 1.46 0.57 
DTX1 2.63 1.59 0.97 0.67 1.17 2.29 
E2F4 1.46 1.88 0.82 0.74 1.23 1.08 
EP300 2.75 1.83 1.32 2.84 1.56 1.80 
FGF1 2.75 1.75 0.74 0.48 3.20 2.41 
FGF2 2.70 1.87 1.81 2.01 2.23 2.32 
FGF3 2.67 0.81 0.75 0.79 1.17 2.05 
FGF4 2.78 1.02 0.84 0.51 1.15 1.90 
FRAT1 3.29 1.44 0.89 0.60 1.10 2.05 
FZD1 2.03 0.78 0.86 0.61 0.85 1.23 
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GADD45A 2.21 0.69 0.90 0.65 1.72 1.85 
HUS1 2.24 1.18 0.71 0.75 2.50 1.53 
JAG1 6.59 0.83 1.58 2.53 2.57 1.69 
KNTC1 2.15 1.78 0.99 0.87 1.35 2.02 
LGR5 3.16 1.33 0.91 1.10 1.91 3.07 
MAD2L1 1.07 1.22 1.10 1.18 1.74 1.19 
MAD2L2 1.47 0.97 0.86 0.63 1.31 1.56 
MKI67 1.20 1.41 1.03 0.97 1.20 1.33 
MYC 3.03 0.88 0.87 0.87 1.47 2.34 
MYST1 1.45 1.86 1.18 1.16 2.27 2.09 
NBN 1.51 0.84 0.57 0.53 2.03 1.24 
NEUROG2 2.86 2.71 1.16 0.70 1.92 2.90 
NFATC1 3.70 1.97 0.94 0.63 1.22 2.29 
NOTCH1 3.89 1.43 0.74 0.54 2.00  - 
NOTCH2 1.15 3.93 0.78 0.70 1.02 1.07 
NUMB 2.74 0.79 1.03 0.78 1.12 1.62 
OLFM4 3.27 0.93 0.73 0.94 1.31 3.11 
PARD6A 3.16 0.79 1.05 2.60 1.94 2.46 
PCNA 1.67 1.37 1.26 0.88 1.18 1.41 
PPARD 3.10 1.56 1.43 2.37 1.86 1.62 
RAD1 1.75 1.29 1.02 0.72 2.34 1.74 
RAD17 1.59 0.89 1.08 0.86 1.42 1.99 
RAD9A 2.01 0.60 0.87 0.62 1.37 1.51 
RB1 1.70 2.01 0.70 0.59 1.81 1.35 
RBBP8 1.32 2.51 0.88 0.47 1.67 1.05 
SKP2 1.64 1.25 0.88 0.75 1.57 1.33 
SOX2 2.71 1.08 1.02 2.57 2.66 1.45 
TFDP1 2.35 0.95 0.91 1.31 1.89 0.99 
TFDP2 1.73 0.41 0.75 0.82 1.56 1.82 
TP53 2.29 0.63 0.68 0.98 0.62 2.01 
WNT1 3.18 1.13 0.62 0.36 0.82 1.48 
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Appendix III 
Materials and Methods 
 
Cell Lines and CFSE Labeling 
 Adherent HCT116 (ATCC CCL-247) and MDA-MB-231 (ATCC HTB-26) 
cultures were grown in DMEM (Gibco 11995) or RPMI (Gibco 22400) respectively with 
10% FBS and 1% Penicillin/Streptomycin. 
 Sphere cultures were grown in Sphere media consisting of DMEM/F12 (Gibco 
11320) with 1X B-27 (Gibco 12587), 15 mM HEPES (Gibco 15630), 1% 
Penicillin/Streptomycin, 20 ng/ml bFGF (Invitrogen 13256-029), and 10 ng/ml EFG 
(Sigma E9644). Spheres were digested in alkaline solution (Sphere media with NaOH, 
pH 11.6) and quenched with acidic solution (Sphere media with HCl, pH 1.7) then 
filtered through a 40 µM mesh.  
 Lentiviruses containing TRCN-shRNA constructs against p35 were purchased 
from the University of Massachusetts Medical School RNAi Core Facility (RHS4459, 
TRCN0000006218, and TRCN0000006220).  HCT116 cells transduced with shRNA 
were cultured in Complete DMEM containing 2 µg/ml puromyocin.   A pCMV-SPORT6 
vector containing the p35 cDNA was purchased from Open Biosystems (MSH1010-
58341) and transfected into cells using X-tremegene HD (Roche 06366244001).  An 
empty pCMV-SPORT6 control vector was created by removing the p35 cDNA between 
EcoRV and Not1 sites, blunting overhangs with Klenow (New England Biolabs 
 134 
M0210S), and ligating with T4 Ligase (New England Biolabs M0202S).  Adherent lines 
were periodically checked by qPCR to confirm knockdown. 
 CFSE (carboxyfluorescein diacetate, succinimidyl ester) labeling was conducted 
with 10 µM CFSE stock according to manufacturer’s protocol for cells in suspension 
(Molecular Probes C34554).     
 
Mice and Tumor Xenografts 
 NOD.CB17-Prkdc scid/J mice were purchased from Jackson Laboratories and 
housed in the UMass Animal Medicine Facilities. NOD-scid IL2rγnull mice were kindly 
provided by Dr. Dale Greiner of the University of Massachusetts Medical School. All 
animals were housed in the UMass Animal Medicine Facilities and experiments were 
conducted under IACUC approval.  
 Adherent HCT116 (1x107) or MDA-MB-231 (7x106) CFSE labeled cells were 
suspended in Matrigel (BD Biosciences 354234) and injected sub-cutaneously into the 
flank or #3 mammary fat pad, respectively.  After two weeks, two to four tumor digests 
were combined to obtain adequate cell numbers and live sorted.   
 Primary patient tumor tissue was obtained from the UMass Cancer Center Tissue 
and Tumor Bank with IRB approval or the Eastern Division of the Cooperative Human 
Tissue Network (CHTNED) and was exclusively passaged in NOD-scid IL2rγnull mice. 
2597T Primary Breast Tumor:  Invasive metaplastic carcinoma.  Grade 3.  ER, PR, HER-
2 negative.  Patient received neoadjuvant chemotherapy without significant response. 
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2953T Primary Colon Tumor:  Invasive adenocarcinoma with positive lymph nodes.  
Moderately differentiated, Grade 2.   
48116 Primary Colon Tumor:  Invasive adenocarcinoma with venous invasion and no 
positive lymph nodes.  Poorly differentiated.  No chemotherapy or radiation. 
 To obtain single cell suspensions, tumors were mechanically and enzymatically (2 
mg/ml collagenase) digested, dissociated on a gentleMACs Dissociator (Miltenyi 
Biotech), and filtered through a 40 µM mesh and labeled as previously described. 
 
Chemotherapy Enrichment Assays  
 Normal and shp35 cell lines were cultured in Sphere media for at least one week 
and passaged once before use.  P35-CMV transfected lines were used immediately 
following three days of transfection.  Single cell suspensions of CFSE-labeled cells were 
plated at 4.0x104 cells/ml.  One week chased single cell suspensions were re-plated at 
4.0x104 cells/ml in Sphere media containing either DMSO vehicle control, 2 µM 
Oxaliplatin (Sigma 9512), 250 µM 5-Fluorouracil (Sigma F6627), or FOX (Oxaliplatin 
and 5-fluorouracil) for three days before being analyzed for CFSE content.  Alternately, 
FOX treated cultures were re-plated in fresh Sphere media containing 10 µM BrdU (BD 
Pharmingen 550891) for 3 days. 
 Mice were injected with 5x106 HCT116 CFSE labeled cells into the #3 and #8 
mammary fat pads.  Twelve days after engraftment (day 0) mice (n=4/condition) were 
injected IP with 40mg/kg 5FU and 10mg/kg Oxali or DMSO diluted in PBS.  Injections 
were repeated on day 4 and day 8.  On day 12, tumors were collected and processed as 
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described.  BrdU pulsed tumors received 1mg BrdU by IP injection on days 14, 15, and 
16, and were processed on day 17.   
 
Flow Cytometry 
 Single cell suspensions derived from sphere cultures were washed in PBS+ (PBS 
with 1% 1M HEPES and 2% FBS).  Single cell in vivo tumor digests were washed in 
PBS+ and stained with the epithelial positive selection marker EpCAM (eBiosciences 50-
9326) and the negative selection markers TER119, CD31, and CD45 (BD Pharmingen 
553673, 553373, and 553089).  In vitro and in vivo samples were suspended in PBS and 
20% Sphere media with 7AAD (BD Pharmingen 559925).   A maximum of 5% of the 
most CFSE intense-Live/Lineage negative cells were collected.  Live cells were sorted 
into complete Sphere media. 
 Tumor initiation dilution analysis was performed by first counting live sorted 
cells and then replating in Sphere media or resuspending in Matrigel before injection into 
the mammary fat pads of NOD.CB17-Prkdc scid/J mice at indicated dilutions.  Spheres 
were counted and measured using the measure function on Image J software 
(http://rsbweb.nih.gov/ij/index.html) after one week of growth.  Dilution cohorts of both 
CFSE-high and CFSE-low mice were sacrificed and tumors were collected and measured 
after the first tumor in the cohort reached ~1000mm3.  Cohorts without visible tumor 
growth after 3 months were sacrificed and examined for tumors. 
 Chemotherapy treated samples and BrdU treated samples were labeled with the 
viability discriminator Live/Dead Blue (Invitrogen L23105) and fixed in Cytofix buffer 
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(BD Biosciences 51-2090KZ).  BrdU treated samples were stained with anti-BrdU 
antibody (Roche 11170376001, APC secondary Santa Cruz sc-3818).  Final samples 
were suspended in FACS Buffer (1x PBS, 1mM sodium azide, and 0.05 g/ml BSA).  Cell 
cycle analysis was performed on cytofixed cells in DAPI (Roche 236276). 
 Cancer stem cell marker analysis was performed on CFSE pulse/chased spheres at 
1 week or tumors after two weeks.  Spheres/tumors were digested and labeled with 
Live/Dead Blue as described and then stained with primary antibodies against CD133 
(Miltenyi Biotec 293C3), CD44 (Millipore MAB4065), or ALDH (BD 611194) and 
secondary antibody anti-mouse PE (Santa Cruz Biotec sc-3738).   
 Side population analysis was performed on CFSE pulse/chased spheres digested 
and viability labeled as described above.  Live cells were incubated at 37 °C for 90 
minutes in 5 µg/ml Hoechst 33342 (Invitrogen H1399) with or without 2.5 µM 
Fumitremorgin C (FTC, Enzo Life Sciences 350-127-C250). 
 All samples were analyzed and sorted by the UMass Medical School Flow 
Cytometry Facility on a BD FACS Aria II or on a BD LSRII.  The proliferation wizard 
from the Modfit analysis package was used to generate peaks from HCT116 in vivo 
xenografts at two weeks. 
 
Immunoprecipitation and Western Blot 
 CDK5, p35, p-BCL2, and IgG antibodies were purchased from Santa Cruz 
Biotechonology (173, 820, 21864, 2027).  PHF-1 antibody was obtained from Peter 
Davies at Albert Einstein College of Medicine.  Tubulin antibody was purchased from 
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Sigma (T9026).  BCL2, Anti-Rabbit HRP, and Anti-Mouse HRP were purchased from 
Dako (M0887, P0448, and P0260) 
 Western blot lysates were prepared in Cell Lysis Buffer (Cell Signaling 9803S) 
with Protease Inhibitor Cocktail (Sigma P-2704).  Proteins were run on an acrylamide gel 
and transferred to an Immobilon-P PVDF (Millipore IPVH00010) membrane.  
Membranes were blocked in PBS with 0.1% Tween-20 and 5% Milk.  
 Immunoprecipitations were performed using the Pierce® Crosslink 
Immunoprecipitation Kit according to the manufacturer’s protocol (26147). 
 
RT-PCR Array Profiling and qPCR 
 RNA was isolated using the Qiagen RNeasy® Mini Kit (74104) and cDNA was 
generated following the protocol described for the RT2 First Strand Kit (SABiosciences 
PP4067). 
 qPCR was performed using Power SYBR Green (Applied Biosystems 4367659) 
with p35 primers (Fw: AAGAACGCCAAGGACAAGAA, Rv: 
TCATTGTTGAGGTGCGTGAT) and GAPDH primers (Fw: 
GAAATCCCATCACCATCTTCCAG, Rv: ATGAGTCCTTCCACGATACCAAAG).   
 A customized RT2 Profiler PCR Array System was purchased from 
SABiosciences (CAPH09537A) and run on an ABI 9700HT following manufacturer 
protocol. 
 
Staining 
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 Tumor samples were frozen in OCT compound, sectioned at 6 µm thickness, 
fixed in 4% paraformaldehyde and stained with H&E stains.  Fluorescent stains were 
mounted with Vectashield containing DAPI (Vector H-1200).   
 Cells for immunofluorescent staining were grown as adherent cultures on cover 
slips and fixed for 5 min in 4% paraformaldehyde.  Cells were then washed in PBS and 
blocked in PBS with .1% Triton X-100 and 5% goat serum for 1 hr.  Primary antibodies 
for staining were the same as those used for western blotting.  Secondary antibodies used 
were Anti-mouse Cy3 (Millipore Ap124C) and anti-Rabbit FitC (Jackson 
ImmnuoResearch 111-096-144). 
 Rectal tumor samples were obtained from the UMass Cancer Center Tissue and 
Tumor Bank.  Immunohistochemical stains were performed by the UMass Memorial 
Pathology Department.  Primary p35 antibody was purchased from Abgent (AP7743a). 
 
Statistics 
 Statistical analysis and p-values were calculated using the t-test functions of the 
GraphPad Prism software. 
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Appendix IV 
Alternative Experiments and Future Directions 
 
 The use of CFSE and development of a protocol to positively identify and isolate 
live slow-cycling cancer cells is a major strength throughout this body of work.  This 
technique has the potential to be universally applicable to cell lines, but this potential was 
not fully explored here as the majority of assays were performed in only the HCT116 cell 
line.  Expansion of the CFSE protocol and assessment of slow-cycling characteristics in 
an additional colon tumor line, two breast tumor lines, and additional primary tumor 
samples would confirm that the phenomena observed are not cell line specific.  
Expansion to more cell lines would also allow a more in-depth exploration of the 
relationship of slow-cycling cells and the CSC phenotype.  The use of additional cell 
lines may suggest a more intersecting relationship between CSCs and slow-cycling cells 
that is consistent with the work of other researchers that demonstrated a stronger CSC 
phenotype within slow-cycling cells (40, 62, 71, 72). 
 The use of qPCR profiling array was a relatively inexpensive, although limiting, 
way to explore predictable differences in slow-cycling cells and rapidly proliferating cells 
across multiple cell lines and tumor types.  Repeating these arrays to increase the power 
of the study and to expand to multiple tumor types would greatly support our findings.  
Alternatively, high throughput deep sequencing techniques to compare the two 
populations would allow for a more unbiased approach and the identification of 
potentially thousands more dysregulated transcripts. 
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 While the shp35 and CMV-p35 knockdown and expression studies began to shed 
light on the importance and role of p35 in tumors, the vectors utilized were not optimal 
for the studies performed.  Recloning of both the over-expression and knockdown vectors 
into selectable and inducible lenti-viral models would greatly enhance the capabilities of 
these studies.  Selectable lenti-viral vectors would allow for more reliable and uniform 
transductions and the potential to move these vectors into primary samples more easily.  
By making the vectors inducible, we gain the ability to better regulate how much protein 
is expressed based on concentration of induction agent.  In this way, it would be possible 
to better titer over-expression of p35 to more physiologically relevant levels and 
potentially increase the knockdown levels to greater than 50%.  Additionally, inducible 
vectors would better facilitate understanding the role of p35 in an in vivo chemotherapy 
model by allowing us to mimic p35 inhibition at various stages of chemotherapy (before, 
during, and after) and test for changes in tumor growth or recurrence. 
 External events prevented a more in-depth study of the relevant targets for p35.  
Further exploration of the mechanisms of cell cycle inhibition, specifically localization, 
binding interactions, and activity states of p27, Rb, and E2F would further define the role 
of p35 in cell cycle regulation of cancer.   Specifically, determining if p35/CDK5 is able 
to complex with p27 and sequester E2F.  Additionally, exploration into the mechanism 
by which p35 regulates BCL2 would also greatly benefit this project.  Determining if p35 
can directly bind and regulate BCL2 and/or alter the Erb pathway or PI3K/AKT kinase 
are important questions in further research into p35 in cancer.    
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 Finally, future work evaluating the role of p35 in tumors should focus on 
migration regulation and the potential for changes in invasion and metastasis in cancer.  
p35 is well studied in neuronal precursor regulation of migration. The use of over-
expression and knockdown vectors or small molecule inhibitors coupled with migration 
and invasion assays in Boyden chambers may clarify the role for p35 in metastasis.  
Additionally, expansion of p35 over-expression and knockdown into cells and primary 
tumors for the creation of xenografts may lead to differences in invasive potential and the 
ability to metastasize. 
 
 
 
 143 
References 
 
1. Massague J. (2004). G1 cell-cycle control and cancer. Nature 432:298-306. 
2. Harbour JW, RX Luo, A Dei Santi, AA Postigo and DC Dean. (1999). Cdk 
phosphorylation triggers sequential intramolecular interactions that progressively 
block Rb functions as cells move through G1. Cell 98:859-869. 
3. Malumbres M and M Barbacid. (2009). Cell cycle, CDKs and cancer: a 
changing paradigm. Nat Rev Cancer 9:153-166. 
4. Park MT and SJ Lee. (2003). Cell cycle and cancer. J Biochem Mol Biol 
36:60-65. 
5. Cheng T, N Rodrigues, H Shen, Y Yang, D Dombkowski, M Sykes and DT 
Scadden. (2000). Hematopoietic stem cell quiescence maintained by p21cip1/waf1. 
Science 287:1804-1808. 
6. Kippin TE, DJ Martens and D van der Kooy. (2005). p21 loss compromises 
the relative quiescence of forebrain stem cell proliferation leading to exhaustion of 
their proliferation capacity. Genes Dev 19:756-767. 
7. Matsumoto A, S Takeishi, T Kanie, E Susaki, I Onoyama, Y Tateishi, K 
Nakayama and KI Nakayama. (2011). p57 is required for quiescence and 
maintenance of adult hematopoietic stem cells. Cell Stem Cell 9:262-271. 
8. Krishnamurthy J, MR Ramsey, KL Ligon, C Torrice, A Koh, S Bonner-Weir 
and NE Sharpless. (2006). p16INK4a induces an age-dependent decline in islet 
regenerative potential. Nature 443:453-457. 
9. Pei XH, F Bai, MD Smith and Y Xiong. (2007). p18Ink4c collaborates with 
Men1 to constrain lung stem cell expansion and suppress non-small-cell lung 
cancers. Cancer Res 67:3162-3170. 
10. Molofsky AV, SG Slutsky, NM Joseph, S He, R Pardal, J Krishnamurthy, 
NE Sharpless and SJ Morrison. (2006). Increasing p16INK4a expression decreases 
forebrain progenitors and neurogenesis during ageing. Nature 443:448-452. 
11. Lalioti V, D Pulido and IV Sandoval. (2010). Cdk5, the multifunctional 
surveyor. Cell Cycle 9:284-311. 
12. Paglini G and A Caceres. (2001). The role of the Cdk5--p35 kinase in 
neuronal development. Eur J Biochem 268:1528-1533. 
13. Morgan DO. (1995). Principles of CDK regulation. Nature 374:131-134. 
14. Zhang J, H Li, O Yabut, H Fitzpatrick, G D'Arcangelo and K Herrup. 
(2010). Cdk5 suppresses the neuronal cell cycle by disrupting the E2F1-DP1 
complex. J Neurosci 30:5219-5228. 
15. Zhang J, H Li and K Herrup. (2010). Cdk5 nuclear localization is p27-
dependent in nerve cells: implications for cell cycle suppression and caspase-3 
activation. J Biol Chem 285:14052-14061. 
16. Mao D and PW Hinds. (2010). p35 is required for CDK5 activation in 
cellular senescence. J Biol Chem 285:14671-14680. 
17. Watt FM and KB Jensen. (2009). Epidermal stem cell diversity and 
quiescence. EMBO Mol Med 1:260-267. 
 144 
18. Reya T, SJ Morrison, MF Clarke and IL Weissman. (2001). Stem cells, 
cancer, and cancer stem cells. Nature 414:105-111. 
19. Cotsarelis G, TT Sun and RM Lavker. (1990). Label-retaining cells reside in 
the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, 
and skin carcinogenesis. Cell 61:1329-1337. 
20. Lyle S, M Christofidou-Solomidou, Y Liu, DE Elder, S Albelda and G 
Cotsarelis. (1998). The C8/144B monoclonal antibody recognizes cytokeratin 15 and 
defines the location of human hair follicle stem cells. J Cell Sci 111 ( Pt 21):3179-
3188. 
21. Clayton E, DP Doupe, AM Klein, DJ Winton, BD Simons and PH Jones. 
(2007). A single type of progenitor cell maintains normal epidermis. Nature 446:185-
189. 
22. Welm BE, SB Tepera, T Venezia, TA Graubert, JM Rosen and MA Goodell. 
(2002). Sca-1(pos) cells in the mouse mammary gland represent an enriched 
progenitor cell population. Dev Biol 245:42-56. 
23. Shackleton M, F Vaillant, KJ Simpson, J Stingl, GK Smyth, ML Asselin-
Labat, L Wu, GJ Lindeman and JE Visvader. (2006). Generation of a functional 
mammary gland from a single stem cell. Nature 439:84-88. 
24. Potten CS, M Kellett, SA Roberts, DA Rew and GD Wilson. (1992). 
Measurement of in vivo proliferation in human colorectal mucosa using 
bromodeoxyuridine. Gut 33:71-78. 
25. Barker N, JH van Es, J Kuipers, P Kujala, M van den Born, M Cozijnsen, A 
Haegebarth, J Korving, H Begthel, PJ Peters and H Clevers. (2007). Identification 
of stem cells in small intestine and colon by marker gene Lgr5. Nature 449:1003-
1007. 
26. Leong KG, BE Wang, L Johnson and WQ Gao. (2008). Generation of a 
prostate from a single adult stem cell. Nature 456:804-808. 
27. Uchida N, DW Buck, D He, MJ Reitsma, M Masek, TV Phan, AS 
Tsukamoto, FH Gage and IL Weissman. (2000). Direct isolation of human central 
nervous system stem cells. Proc Natl Acad Sci U S A 97:14720-14725. 
28. Osawa M, K Hanada, H Hamada and H Nakauchi. (1996). Long-term 
lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic 
stem cell. Science 273:242-245. 
29. Morrison SJ and IL Weissman. (1994). The long-term repopulating subset of 
hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 
1:661-673. 
30. Coller HA, L Sang and JM Roberts. (2006). A new description of cellular 
quiescence. PLoS Biol 4:e83. 
31. Sang L, HA Coller and JM Roberts. (2008). Control of the reversibility of 
cellular quiescence by the transcriptional repressor HES1. Science 321:1095-1100. 
32. Viatour P, TC Somervaille, S Venkatasubrahmanyam, S Kogan, ME 
McLaughlin, IL Weissman, AJ Butte, E Passegue and J Sage. (2008). Hematopoietic 
stem cell quiescence is maintained by compound contributions of the retinoblastoma 
gene family. Cell Stem Cell 3:416-428. 
 145 
33. Lyle S, M Christofidou-Solomidou, Y Liu, DE Elder, S Albelda and G 
Cotsarelis. (1999). Human hair follicle bulge cells are biochemically distinct and 
possess an epithelial stem cell phenotype. J Investig Dermatol Symp Proc 4:296-301. 
34. Roh C, M Roche, Z Guo, C Photopoulos, Q Tao and S Lyle. (2008). Multi-
potentiality of a new immortalized epithelial stem cell line derived from human hair 
follicles. In Vitro Cell Dev Biol Anim 44:236-244. 
35. Jaks V, N Barker, M Kasper, JH van Es, HJ Snippert, H Clevers and R 
Toftgard. (2008). Lgr5 marks cycling, yet long-lived, hair follicle stem cells. Nat 
Genet 40:1291-1299. 
36. Potten CS. (1998). Stem cells in gastrointestinal epithelium: numbers, 
characteristics and death. Philos Trans R Soc Lond B Biol Sci 353:821-830. 
37. Nishimura S, N Wakabayashi, K Toyoda, K Kashima and S Mitsufuji. 
(2003). Expression of Musashi-1 in human normal colon crypt cells: a possible stem 
cell marker of human colon epithelium. Dig Dis Sci 48:1523-1529. 
38. Potten CS, C Booth, GL Tudor, D Booth, G Brady, P Hurley, G Ashton, R 
Clarke, S Sakakibara and H Okano. (2003). Identification of a putative intestinal 
stem cell and early lineage marker; musashi-1. Differentiation 71:28-41. 
39. Ricci-Vitiani L, E Fabrizi, E Palio and R De Maria. (2009). Colon cancer 
stem cells. J Mol Med. 
40. Pece S, D Tosoni, S Confalonieri, G Mazzarol, M Vecchi, S Ronzoni, L 
Bernard, G Viale, PG Pelicci and PP Di Fiore. (2010). Biological and molecular 
heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 
140:62-73. 
41. Visvader JE and GJ Lindeman. (2006). Mammary stem cells and 
mammopoiesis. Cancer Res 66:9798-9801. 
42. Morshead CM, BA Reynolds, CG Craig, MW McBurney, WA Staines, D 
Morassutti, S Weiss and D van der Kooy. (1994). Neural stem cells in the adult 
mammalian forebrain: a relatively quiescent subpopulation of subependymal cells. 
Neuron 13:1071-1082. 
43. Tsujimura A, Y Koikawa, S Salm, T Takao, S Coetzee, D Moscatelli, E 
Shapiro, H Lepor, TT Sun and EL Wilson. (2002). Proximal location of mouse 
prostate epithelial stem cells: a model of prostatic homeostasis. J Cell Biol 157:1257-
1265. 
44. Teng C, Y Guo, H Zhang, M Ding and H Deng. (2007). Identification and 
characterization of label-retaining cells in mouse pancreas. Differentiation 75:702-
712. 
45. Society AC. (2012). Cancer Facts & Figures 2012. AAC Society, ed. 
46. Gill S, CL Loprinzi, DJ Sargent, SD Thome, SR Alberts, DG Haller, J 
Benedetti, G Francini, LE Shepherd, J Francois Seitz, R Labianca, W Chen, SS 
Cha, MP Heldebrant and RM Goldberg. (2004). Pooled analysis of fluorouracil-
based adjuvant therapy for stage II and III colon cancer: who benefits and by how 
much? J Clin Oncol 22:1797-1806. 
47. Hanahan D and RA Weinberg. (2000). The hallmarks of cancer. Cell 100:57-
70. 
 146 
48. Dean M. (2006). Cancer stem cells: redefining the paradigm of cancer 
treatment strategies. Mol Interv 6:140-148. 
49. Woodward WA, MS Chen, F Behbod and JM Rosen. (2005). On mammary 
stem cells. J Cell Sci 118:3585-3594. 
50. Blanpain C and E Fuchs. (2009). Epidermal homeostasis: a balancing act of 
stem cells in the skin. Nat Rev Mol Cell Biol 10:207-217. 
51. Kangsamaksin T, HJ Park, CS Trempus and RJ Morris. (2007). A 
perspective on murine keratinocyte stem cells as targets of chemically induced skin 
cancer. Mol Carcinog 46:579-584. 
52. Al-Hajj M, MS Wicha, A Benito-Hernandez, SJ Morrison and MF Clarke. 
(2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad 
Sci U S A 100:3983-3988. 
53. Jordan CT, ML Guzman and M Noble. (2006). Cancer stem cells. N Engl J 
Med 355:1253-1261. 
54. Ricci-Vitiani L, A Pagliuca, E Palio, A Zeuner and R De Maria. (2008). 
Colon cancer stem cells. Gut 57:538-548. 
55. Visvader JE and GJ Lindeman. (2008). Cancer stem cells in solid tumours: 
accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768. 
56. Bonnet D and JE Dick. (1997). Human acute myeloid leukemia is organized 
as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-
737. 
57. Collins AT, PA Berry, C Hyde, MJ Stower and NJ Maitland. (2005). 
Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 
65:10946-10951. 
58. Li C, DG Heidt, P Dalerba, CF Burant, L Zhang, V Adsay, M Wicha, MF 
Clarke and DM Simeone. (2007). Identification of pancreatic cancer stem cells. 
Cancer Res 67:1030-1037. 
59. O'Brien CA, A Pollett, S Gallinger and JE Dick. (2007). A human colon 
cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 
445:106-110. 
60. Ricci-Vitiani L, DG Lombardi, E Pilozzi, M Biffoni, M Todaro, C Peschle 
and R De Maria. (2007). Identification and expansion of human colon-cancer-
initiating cells. Nature 445:111-115. 
61. Chu P, DJ Clanton, TS Snipas, J Lee, E Mitchell, ML Nguyen, E Hare and 
RJ Peach. (2009). Characterization of a subpopulation of colon cancer cells with 
stem cell-like properties. Int J Cancer 124:1312-1321. 
62. Gao MQ, YP Choi, S Kang, JH Youn and NH Cho. (2010). CD24+ cells from 
hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 
29:2672-2680. 
63. Singh SK, C Hawkins, ID Clarke, JA Squire, J Bayani, T Hide, RM 
Henkelman, MD Cusimano and PB Dirks. (2004). Identification of human brain 
tumour initiating cells. Nature 432:396-401. 
64. Shmelkov SV, JM Butler, AT Hooper, A Hormigo, J Kushner, T Milde, R St 
Clair, M Baljevic, I White, DK Jin, A Chadburn, AJ Murphy, DM Valenzuela, NW 
 147 
Gale, G Thurston, GD Yancopoulos, M D'Angelica, N Kemeny, D Lyden and S 
Rafii. (2008). CD133 expression is not restricted to stem cells, and both CD133+ and 
CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111-2120. 
65. Kemper K, MR Sprick, M de Bree, A Scopelliti, L Vermeulen, M Hoek, J 
Zeilstra, ST Pals, H Mehmet, G Stassi and JP Medema. (2010). The AC133 epitope, 
but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 
70:719-729. 
66. Gires O. (2011). Lessons from common markers of tumor-initiating cells in 
solid cancers. Cell Mol Life Sci 68:4009-4022. 
67. Diehn M and MF Clarke. (2006). Cancer stem cells and radiotherapy: new 
insights into tumor radioresistance. J Natl Cancer Inst 98:1755-1757. 
68. Fillmore CM and C Kuperwasser. (2008). Human breast cancer cell lines 
contain stem-like cells that self-renew, give rise to phenotypically diverse progeny 
and survive chemotherapy. Breast Cancer Res 10:R25. 
69. Minn AJ, Y Kang, I Serganova, GP Gupta, DD Giri, M Doubrovin, V 
Ponomarev, WL Gerald, R Blasberg and J Massague. (2005). Distinct organ-specific 
metastatic potential of individual breast cancer cells and primary tumors. J Clin 
Invest 115:44-55. 
70. Uchino M, H Kojima, K Wada, M Imada, F Onoda, H Satofuka, T Utsugi 
and Y Murakami. (2010). Nuclear beta-catenin and CD44 upregulation characterize 
invasive cell populations in non-aggressive MCF-7 breast cancer cells. BMC Cancer 
10:414. 
71. Roesch A, M Fukunaga-Kalabis, EC Schmidt, SE Zabierowski, PA Brafford, 
A Vultur, D Basu, P Gimotty, T Vogt and M Herlyn. (2010). A temporarily distinct 
subpopulation of slow-cycling melanoma cells is required for continuous tumor 
growth. Cell 141:583-594. 
72. Dembinski JL and S Krauss. (2009). Characterization and functional 
analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. 
Clin Exp Metastasis 26:611-623. 
73. Mani SA, W Guo, MJ Liao, EN Eaton, A Ayyanan, AY Zhou, M Brooks, F 
Reinhard, CC Zhang, M Shipitsin, LL Campbell, K Polyak, C Brisken, J Yang and 
RA Weinberg. (2008). The epithelial-mesenchymal transition generates cells with 
properties of stem cells. Cell 133:704-715. 
74. Ben-Porath I, MW Thomson, VJ Carey, R Ge, GW Bell, A Regev and RA 
Weinberg. (2008). An embryonic stem cell-like gene expression signature in poorly 
differentiated aggressive human tumors. Nat Genet 40:499-507. 
75. Reya T and H Clevers. (2005). Wnt signalling in stem cells and cancer. 
Nature 434:843-850. 
76. Turton NJ, DJ Judah, J Riley, R Davies, D Lipson, JA Styles, AG Smith and 
TW Gant. (2001). Gene expression and amplification in breast carcinoma cells with 
intrinsic and acquired doxorubicin resistance. Oncogene 20:1300-1306. 
77. Qiu W, EB Carson-Walter, H Liu, M Epperly, JS Greenberger, GP 
Zambetti, L Zhang and J Yu. (2008). PUMA regulates intestinal progenitor cell 
radiosensitivity and gastrointestinal syndrome. Cell Stem Cell 2:576-583. 
 148 
78. Eyler CE and JN Rich. (2008). Survival of the fittest: cancer stem cells in 
therapeutic resistance and angiogenesis. J Clin Oncol 26:2839-2845. 
79. Bao S, Q Wu, RE McLendon, Y Hao, Q Shi, AB Hjelmeland, MW Dewhirst, 
DD Bigner and JN Rich. (2006). Glioma stem cells promote radioresistance by 
preferential activation of the DNA damage response. Nature 444:756-760. 
80. Dekaney CM, AS Gulati, AP Garrison, MA Helmrath and SJ Henning. 
(2009). Regeneration of intestinal stem/progenitor cells following doxorubicin 
treatment of mice. Am J Physiol Gastrointest Liver Physiol 297:G461-470. 
81. Merritt AJ, CS Potten, AJ Watson, DY Loh, K Nakayama and JA Hickman. 
(1995). Differential expression of bcl-2 in intestinal epithelia. Correlation with 
attenuation of apoptosis in colonic crypts and the incidence of colonic neoplasia. J 
Cell Sci 108 ( Pt 6):2261-2271. 
82. Naumov GN, JL Townson, IC MacDonald, SM Wilson, VH Bramwell, AC 
Groom and AF Chambers. (2003). Ineffectiveness of doxorubicin treatment on 
solitary dormant mammary carcinoma cells or late-developing metastases. Breast 
Cancer Res Treat 82:199-206. 
83. Hambardzumyan D, OJ Becher, MK Rosenblum, PP Pandolfi, K Manova-
Todorova and EC Holland. (2008). PI3K pathway regulates survival of cancer stem 
cells residing in the perivascular niche following radiation in medulloblastoma in 
vivo. Genes Dev 22:436-448. 
84. Thames HD, AC Ruifrok, L Milas, N Hunter, KA Mason, NH Terry and RA 
White. (1996). Accelerated repopulation during fractionated irradiation of a murine 
ovarian carcinoma: downregulation of apoptosis as a possible mechanism. Int J 
Radiat Oncol Biol Phys 35:951-962. 
85. Todaro M, M Perez Alea, A Scopelliti, JP Medema and G Stassi. (2008). IL-
4-mediated drug resistance in colon cancer stem cells. Cell Cycle 7:309-313. 
86. Thomadaki H and A Scorilas. (2006). BCL2 family of apoptosis-related 
genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 43:1-67. 
87. Ryan JA, JK Brunelle and A Letai. (2010). Heightened mitochondrial 
priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc 
Natl Acad Sci U S A 107:12895-12900. 
88. Cory S and JM Adams. (2002). The Bcl2 family: regulators of the cellular 
life-or-death switch. Nat Rev Cancer 2:647-656. 
89. Phillips TM, WH McBride and F Pajonk. (2006). The response of CD24(-
/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98:1777-
1785. 
90. Perucca P, O Cazzalini, M Madine, M Savio, RA Laskey, V Vannini, E 
Prosperi and LA Stivala. (2009). Loss of p21 CDKN1A impairs entry to quiescence 
and activates a DNA damage response in normal fibroblasts induced to quiescence. 
Cell Cycle 8:105-114. 
91. Sage J, AL Miller, PA Perez-Mancera, JM Wysocki and T Jacks. (2003). 
Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. 
Nature 424:223-228. 
 149 
92. Forsberg EC, E Passegue, SS Prohaska, AJ Wagers, M Koeva, JM Stuart 
and IL Weissman. (2010). Molecular signatures of quiescent, mobilized and 
leukemia-initiating hematopoietic stem cells. PLoS ONE 5:e8785. 
93. Shimojo H, T Ohtsuka and R Kageyama. (2008). Oscillations in notch 
signaling regulate maintenance of neural progenitors. Neuron 58:52-64. 
94. Liu S, G Dontu, ID Mantle, S Patel, NS Ahn, KW Jackson, P Suri and MS 
Wicha. (2006). Hedgehog signaling and Bmi-1 regulate self-renewal of normal and 
malignant human mammary stem cells. Cancer Res 66:6063-6071. 
95. Horsley V, AO Aliprantis, L Polak, LH Glimcher and E Fuchs. (2008). 
NFATc1 balances quiescence and proliferation of skin stem cells. Cell 132:299-310. 
96. Cheung ZH, K Gong and NY Ip. (2008). Cyclin-dependent kinase 5 supports 
neuronal survival through phosphorylation of Bcl-2. J Neurosci 28:4872-4877. 
97. Wang CX, JH Song, DK Song, VW Yong, A Shuaib and C Hao. (2006). 
Cyclin-dependent kinase-5 prevents neuronal apoptosis through ERK-mediated 
upregulation of Bcl-2. Cell Death Differ 13:1203-1212. 
98. Lin S, J Wang, Z Ye, NY Ip and SC Lin. (2008). CDK5 activator p35 
downregulates E-cadherin precursor independently of CDK5. FEBS Lett 582:1197-
1202. 
99. Kesavapany S, KF Lau, DM McLoughlin, J Brownlees, S Ackerley, PN 
Leigh, CE Shaw and CC Miller. (2001). p35/cdk5 binds and phosphorylates beta-
catenin and regulates beta-catenin/presenilin-1 interaction. Eur J Neurosci 13:241-
247. 
100. Plattner F, M Angelo and KP Giese. (2006). The roles of cyclin-dependent 
kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 
281:25457-25465. 
101. Bramblett GT, M Goedert, R Jakes, SE Merrick, JQ Trojanowski and VM 
Lee. (1993). Abnormal tau phosphorylation at Ser396 in Alzheimer's disease 
recapitulates development and contributes to reduced microtubule binding. Neuron 
10:1089-1099. 
102. Barker N, RA Ridgway, JH van Es, M van de Wetering, H Begthel, M van 
den Born, E Danenberg, AR Clarke, OJ Sansom and H Clevers. (2009). Crypt stem 
cells as the cells-of-origin of intestinal cancer. Nature 457:608-611. 
103. Vermeulen L, EMF De Sousa, M van der Heijden, K Cameron, JH de Jong, 
T Borovski, JB Tuynman, M Todaro, C Merz, H Rodermond, MR Sprick, K 
Kemper, DJ Richel, G Stassi and JP Medema. (2010). Wnt activity defines colon 
cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12:468-
476. 
104. Lin H, JL Juang and PS Wang. (2004). Involvement of Cdk5/p25 in digoxin-
triggered prostate cancer cell apoptosis. J Biol Chem 279:29302-29307. 
105. Hsu FN, MC Chen, MC Chiang, E Lin, YT Lee, PH Huang, GS Lee and H 
Lin. (2011). Regulation of androgen receptor and prostate cancer growth by cyclin-
dependent kinase 5. J Biol Chem 286:33141-33149. 
106. Abbas T and A Dutta. (2009). p21 in cancer: intricate networks and multiple 
activities. Nat Rev Cancer 9:400-414. 
 150 
107. Shen KC, H Heng, Y Wang, S Lu, G Liu, CX Deng, SC Brooks and YA 
Wang. (2005). ATM and p21 cooperate to suppress aneuploidy and subsequent 
tumor development. Cancer Res 65:8747-8753. 
108. Jackson RJ, J Adnane, D Coppola, A Cantor, SM Sebti and WJ Pledger. 
(2002). Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances 
tumorigenesis in knockout mouse models. Oncogene 21:8486-8497. 
109. Philipp J, K Vo, KE Gurley, K Seidel and CJ Kemp. (1999). Tumor 
suppression by p27Kip1 and p21Cip1 during chemically induced skin 
carcinogenesis. Oncogene 18:4689-4698. 
110. Andre T, C Boni, M Navarro, J Tabernero, T Hickish, C Topham, A Bonetti, 
P Clingan, J Bridgewater, F Rivera and A de Gramont. (2009). Improved overall 
survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in 
stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116. 
111. Brewster AM, GN Hortobagyi, KR Broglio, SW Kau, CA Santa-Maria, B 
Arun, AU Buzdar, DJ Booser, V Valero, M Bondy and FJ Esteva. (2008). Residual 
risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 
100:1179-1183. 
112. Jung Y and SJ Lippard. (2007). Direct cellular responses to platinum-
induced DNA damage. Chem Rev 107:1387-1407. 
113. Papamichael D. (1999). The use of thymidylate synthase inhibitors in the 
treatment of advanced colorectal cancer: current status. Oncologist 4:478-487. 
114. Selleri S, F Arnaboldi, M Palazzo, U Hussein, A Balsari and C Rumio. 
(2005). Caveolin-1 is expressed on multipotent cells of hair follicles and might be 
involved in their resistance to chemotherapy. Br J Dermatol 153:506-513. 
115. Kusumbe AP and SA Bapat. (2009). Cancer stem cells and aneuploid 
populations within developing tumors are the major determinants of tumor 
dormancy. Cancer Res 69:9245-9253. 
116. Grimshaw MJ, L Cooper, K Papazisis, JA Coleman, HR Bohnenkamp, L 
Chiapero-Stanke, J Taylor-Papadimitriou and JM Burchell. (2008). Mammosphere 
culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. 
Breast Cancer Res 10:R52. 
117. Chikamatsu K, H Ishii, G Takahashi, A Okamoto, M Moriyama, K 
Sakakura and K Masuyama. (2011). Resistance to apoptosis-inducing stimuli in 
CD44+ head and neck squamous cell carcinoma cells. Head Neck. 
118. Harper LJ, DE Costea, L Gammon, B Fazil, A Biddle and IC Mackenzie. 
(2010). Normal and malignant epithelial cells with stem-like properties have an 
extended G2 cell cycle phase that is associated with apoptotic resistance. BMC 
Cancer 10:166. 
119. Quintana E, M Shackleton, MS Sabel, DR Fullen, TM Johnson and SJ 
Morrison. (2008). Efficient tumour formation by single human melanoma cells. 
Nature 456:593-598. 
120. Moore N, J Houghton and S Lyle. (2011). Slow-Cycling Therapy-Resistant 
Cancer Cells. Stem Cells Dev. 
 151 
121. Dhariwala FA and MS Rajadhyaksha. (2008). An unusual member of the 
Cdk family: Cdk5. Cell Mol Neurobiol 28:351-369. 
122. Lopes JP and P Agostinho. (2011). Cdk5: multitasking between physiological 
and pathological conditions. Prog Neurobiol 94:49-63. 
123. Chae T, YT Kwon, R Bronson, P Dikkes, E Li and LH Tsai. (1997). Mice 
lacking p35, a neuronal specific activator of Cdk5, display cortical lamination 
defects, seizures, and adult lethality. Neuron 18:29-42. 
124. Schuman EM and S Murase. (2003). Cadherins and synaptic plasticity: 
activity-dependent cyclin-dependent kinase 5 regulation of synaptic beta-catenin-
cadherin interactions. Philos Trans R Soc Lond B Biol Sci 358:749-756. 
125. Wrobel G, P Roerig, F Kokocinski, K Neben, M Hahn, G Reifenberger and P 
Lichter. (2005). Microarray-based gene expression profiling of benign, atypical and 
anaplastic meningiomas identifies novel genes associated with meningioma 
progression. Int J Cancer 114:249-256. 
126. Eggers JP, PM Grandgenett, EC Collisson, ME Lewallen, J Tremayne, PK 
Singh, BJ Swanson, JM Andersen, TC Caffrey, RR High, M Ouellette and MA 
Hollingsworth. (2011). Cyclin-dependent kinase 5 is amplified and overexpressed in 
pancreatic cancer and activated by mutant K-Ras. Clin Cancer Res 17:6140-6150. 
127. Goodyear S and MC Sharma. (2007). Roscovitine regulates invasive breast 
cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory 
protein cdk5. Exp Mol Pathol 82:25-32. 
128. Liu JL, XY Wang, BX Huang, F Zhu, RG Zhang and G Wu. (2011). 
Expression of CDK5/p35 in resected patients with non-small cell lung cancer: 
relation to prognosis. Med Oncol 28:673-678. 
129. Li BS, W Ma, H Jaffe, Y Zheng, S Takahashi, L Zhang, AB Kulkarni and 
HC Pant. (2003). Cyclin-dependent kinase-5 is involved in neuregulin-dependent 
activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal 
survival. J Biol Chem 278:35702-35709. 
130. Kang JS, CJ Lee, JM Lee, JY Rha, KW Song and MH Park. (2003). 
Follicular expression of c-Kit/SCF and inhibin-alpha in mouse ovary during 
development. J Histochem Cytochem 51:1447-1458. 
131. Lopes JP, CR Oliveira and P Agostinho. (2009). Cdk5 acts as a mediator of 
neuronal cell cycle re-entry triggered by amyloid-beta and prion peptides. Cell 
Cycle 8:97-104. 
132. Zhang J, SA Cicero, L Wang, RR Romito-Digiacomo, Y Yang and K Herrup. 
(2008). Nuclear localization of Cdk5 is a key determinant in the postmitotic state of 
neurons. Proc Natl Acad Sci U S A 105:8772-8777. 
133. Zhang J, H Li, T Zhou, J Zhou and K Herrup. (2012). Cdk5 levels oscillate 
during the neuronal cell cycle: Cdh1 ubiquitination triggers proteosome-dependent 
degradation during S-phase. J Biol Chem. 
134. Dalerba P, SJ Dylla, IK Park, R Liu, X Wang, RW Cho, T Hoey, A Gurney, 
EH Huang, DM Simeone, AA Shelton, G Parmiani, C Castelli and MF Clarke. 
(2007). Phenotypic characterization of human colorectal cancer stem cells. Proc Natl 
Acad Sci U S A 104:10158-10163. 
 152 
135. Huang EH, MJ Hynes, T Zhang, C Ginestier, G Dontu, H Appelman, JZ 
Fields, MS Wicha and BM Boman. (2009). Aldehyde dehydrogenase 1 is a marker 
for normal and malignant human colonic stem cells (SC) and tracks SC 
overpopulation during colon tumorigenesis. Cancer Res 69:3382-3389. 
136. Vermeulen L, M Todaro, F de Sousa Mello, MR Sprick, K Kemper, M Perez 
Alea, DJ Richel, G Stassi and JP Medema. (2008). Single-cell cloning of colon cancer 
stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A 
105:13427-13432. 
137. Nagano O and H Saya. (2004). Mechanism and biological significance of 
CD44 cleavage. Cancer Sci 95:930-935. 
138. Zeilstra J, SP Joosten, M Dokter, E Verwiel, M Spaargaren and ST Pals. 
(2008). Deletion of the WNT target and cancer stem cell marker CD44 in 
Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 68:3655-3661. 
139. Wielenga VJ, R Smits, V Korinek, L Smit, M Kielman, R Fodde, H Clevers 
and ST Pals. (1999). Expression of CD44 in Apc and Tcf mutant mice implies 
regulation by the WNT pathway. Am J Pathol 154:515-523. 
140. Bauer N, AV Fonseca, M Florek, D Freund, J Jaszai, M Bornhauser, CA 
Fargeas and D Corbeil. (2008). New insights into the cell biology of hematopoietic 
progenitors by studying prominin-1 (CD133). Cells Tissues Organs 188:127-138. 
141. Freund D, N Bauer, S Boxberger, S Feldmann, U Streller, G Ehninger, C 
Werner, M Bornhauser, J Oswald and D Corbeil. (2006). Polarization of human 
hematopoietic progenitors during contact with multipotent mesenchymal stromal 
cells: effects on proliferation and clonogenicity. Stem Cells Dev 15:815-829. 
142. Zhang M, M Shoeb, J Goswamy, P Liu, TL Xiao, D Hogan, GA Campbell 
and NH Ansari. (2009). Overexpression of aldehyde dehydrogenase 1A1 reduces 
oxidation-induced toxicity in SH-SY5Y neuroblastoma cells. J Neurosci Res 88:686-
694. 
143. Ma I and AL Allan. (2010). The role of human aldehyde dehydrogenase in 
normal and cancer stem cells. Stem Cell Rev 7:292-306. 
144. Szotek PP, R Pieretti-Vanmarcke, PT Masiakos, DM Dinulescu, D Connolly, 
R Foster, D Dombkowski, F Preffer, DT Maclaughlin and PK Donahoe. (2006). 
Ovarian cancer side population defines cells with stem cell-like characteristics and 
Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A 
103:11154-11159. 
145. Patrawala L, T Calhoun, R Schneider-Broussard, J Zhou, K Claypool and 
DG Tang. (2005). Side population is enriched in tumorigenic, stem-like cancer cells, 
whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 
65:6207-6219. 
146. Kondo T, T Setoguchi and T Taga. (2004). Persistence of a small 
subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci 
U S A 101:781-786. 
147. Haraguchi N, T Utsunomiya, H Inoue, F Tanaka, K Mimori, GF Barnard 
and M Mori. (2006). Characterization of a side population of cancer cells from 
human gastrointestinal system. Stem Cells 24:506-513. 
 153 
148. Moserle L, M Ghisi, A Amadori and S Indraccolo. (2009). Side population 
and cancer stem cells: therapeutic implications. Cancer Lett 288:1-9. 
149. Moore N and S Lyle. (2010). Quiescent, slow-cycling stem cell populations in 
cancer: a review of the evidence and discussion of significance. J Oncol 2011. 
150. Kai K, O Nagano, E Sugihara, Y Arima, O Sampetrean, T Ishimoto, M 
Nakanishi, NT Ueno, H Iwase and H Saya. (2009). Maintenance of HCT116 colon 
cancer cell line conforms to a stochastic model but not a cancer stem cell model. 
Cancer Sci. 
151. Yeung TM, SC Gandhi, JL Wilding, R Muschel and WF Bodmer. (2010). 
Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci U S 
A 107:3722-3727. 
152. Smith GH. (2005). Label-retaining epithelial cells in mouse mammary gland 
divide asymmetrically and retain their template DNA strands. Development 
132:681-687. 
153. Xin HW, DM Hari, JE Mullinax, CM Ambe, T Koizumi, S Ray, AJ 
Anderson, GW Wiegand, SH Garfield, SS Thorgeirsson and I Avital. (2012). 
Tumor-initiating label-retaining cancer cells in human gastrointestinal cancers 
undergo asymmetric cell division. Stem Cells 30:591-598. 
154. Parish CR. (1999). Fluorescent dyes for lymphocyte migration and 
proliferation studies. Immunol Cell Biol 77:499-508. 
155. Shapiro GI. (2006). Cyclin-dependent kinase pathways as targets for cancer 
treatment. J Clin Oncol 24:1770-1783. 
156. Senderowicz AM, D Headlee, SF Stinson, RM Lush, N Kalil, L Villalba, K 
Hill, SM Steinberg, WD Figg, A Tompkins, SG Arbuck and EA Sausville. (1998). 
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase 
inhibitor, in patients with refractory neoplasms. J Clin Oncol 16:2986-2999. 
157. Stadler WM, NJ Vogelzang, R Amato, J Sosman, D Taber, D Liebowitz and 
EE Vokes. (2000). Flavopiridol, a novel cyclin-dependent kinase inhibitor, in 
metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin 
Oncol 18:371-375. 
158. Schwartz GK, D Ilson, L Saltz, E O'Reilly, W Tong, P Maslak, J Werner, P 
Perkins, M Stoltz and D Kelsen. (2001). Phase II study of the cyclin-dependent 
kinase inhibitor flavopiridol administered to patients with advanced gastric 
carcinoma. J Clin Oncol 19:1985-1992. 
159. Rathkopf D, MA Dickson, DR Feldman, RD Carvajal, MA Shah, N Wu, R 
Lefkowitz, M Gonen, LM Cane, HJ Dials, JL Winkelmann, GJ Bosl and GK 
Schwartz. (2009). Phase I study of flavopiridol with oxaliplatin and 
fluorouracil/leucovorin in advanced solid tumors. Clin Cancer Res 15:7405-7411. 
160. Gorlick R, EA Kolb, PJ Houghton, CL Morton, G Neale, ST Keir, H Carol, 
R Lock, D Phelps, MH Kang, CP Reynolds, JM Maris, C Billups and MA Smith. 
(2012). Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 
(dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer. 
161. Hassan M, H Sallam and Z Hassan. (2011). The Role of Pharmacokinetics 
and Pharmacodynamics in Early Drug Development with reference to the Cyclin-
 154 
dependent Kinase (Cdk) Inhibitor - Roscovitine. Sultan Qaboos Univ Med J 11:165-
178. 
162. Dickson MA and GK Schwartz. (2009). Development of cell-cycle inhibitors 
for cancer therapy. Curr Oncol 16:36-43. 
 
 
